Microbiota restoration therapy (mrt), compositions and methods of manufacture

ABSTRACT

Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No.14/504,927, filed Oct. 2, 2014, which is a continuation-in-part of U.S.application Ser. No. 14/295,686, filed Jun. 4, 2014, which claimspriority to U.S. Provisional Application Ser. No. 61/831,409, filed Jun.5, 2013, the entirety of each of which are incorporated herein byreference.

TECHNICAL FIELD

The present disclosure pertains to compositions and methods for treatingdiseases and/or conditions of the digestive tract.

BACKGROUND

A wide variety of compositions and methods have been developed fortreating diseases and/or conditions of the digestive track. Of the knowncompositions and methods, each has certain advantages and disadvantages.There is an ongoing need to provide alternative compositions and methodsfor treating diseases and/or conditions of the digestive track.

BRIEF SUMMARY

Microbiota restoration therapy compositions and methods formanufacturing, processing, and/or delivering microbiota restorationtherapy compositions are disclosed. An example method for manufacturinga microbiota restoration therapy composition may include collecting ahuman fecal sample and adding a diluent to the human fecal sample toform a diluted sample. The diluent may include a cryoprotectant. Themethod may also include mixing the diluted sample with a mixingapparatus and filtering the diluted sample. Filtering may form afiltrate. The method may also include transferring the filtrate to asample bag and sealing the sample bag.

An example method for manufacturing, processing, and packaging amicrobiota restoration therapy composition may include collecting afecal sample from a pre-screened donor, transferring the fecal sample toa filter bag, and adding a diluent to the filter bag. The diluent mayinclude a cryoprotectant. The method may also include sealing the filterbag, transferring the sealed filter bag to a mixer, and transferring thefiltrate from the filter bag to a sample bag. Transferring the filtratefrom the filter bag to a sample bag may define the microbiotarestoration therapy composition within the sample bag. The method mayalso include sealing the sample bag, cooling sample bag, andtransferring the cooled sample bag to a controlled temperature storagedevice. Transferring the cooled sample bag to a controlled temperaturestorage device may include freezing the microbiota restoration therapycomposition. The method may also include thawing the frozen microbiotarestoration therapy composition, packaging the sample bag in aninsulated packaging system, and shipping the packaged sample bag to atreatment facility.

An example method for medical treatment may include collecting a fecalsample from a pre-screened donor, transferring the fecal sample to afilter bag, and adding a diluent to the filter bag. The diluent mayinclude a cryoprotectant. The method may also include sealing the filterbag, transferring the sealed filter bag to a mixer, and transferring thefiltrate from the filter bag to a sample bag. Transferring the filtratefrom the filter bag to a sample bag may define a microbiota restorationtherapy composition within the sample bag. The method may also includesealing the sample bag, cooling sample bag, and transferring the cooledsample bag to a controlled temperature storage device. Transferring thecooled sample bag to a controlled temperature storage device may includefreezing the microbiota restoration therapy composition. The method mayalso include thawing the frozen microbiota restoration therapycomposition, packaging the sample bag in an insulated packaging system,shipping the packaged sample bag to a treatment facility, andadministering the microbiota restoration therapy composition to apatient.

The above summary of some embodiments is not intended to describe eachdisclosed embodiment or every implementation of the present disclosure.The Figures, and Detailed Description, which follow, more particularlyexemplify these embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

The disclosure may be more completely understood in consideration of thefollowing detailed description in connection with the accompanyingdrawings, in which:

FIG. 1 is a flow chart schematically depicting a process for collectingand inspecting a donor fecal sample;

FIG. 2 is a flow chart schematically depicting a process for screening afecal donor; FIGS. 3A and 3B are flowcharts depicting an example methodfor manufacturing a microbiota restoration therapy composition;

FIG. 4 is a flowchart depicting an example process for ordering andshipping a microbiota restoration therapy composition;

FIG. 5 is a flowchart depicting another example process for ordering andshipping a microbiota restoration therapy composition;

FIG. 6 is a schematic view of an example packaging system;

FIG. 7 illustrates an example sample bag; and

FIG. 8 illustrates an example tube assembly.

While the disclosure is amenable to various modifications andalternative forms, specifics thereof have been shown by way of examplein the drawings and will be described in detail. It should beunderstood, however, that the intention is not to limit the invention tothe particular embodiments described. On the contrary, the intention isto cover all modifications, equivalents, and alternatives falling withinthe spirit and scope of the disclosure.

DETAILED DESCRIPTION

For the following defined terms, these definitions shall be applied,unless a different definition is given in the claims or elsewhere inthis specification.

All numeric values are herein assumed to be modified by the term“about”, whether or not explicitly indicated. The term “about” generallyrefers to a range of numbers that one of skill in the art would considerequivalent to the recited value (e.g., having the same function orresult). In many instances, the terms “about” may include numbers thatare rounded to the nearest significant figure.

The recitation of numerical ranges by endpoints includes all numberswithin that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and5).

As used in this specification and the appended claims, the singularforms “a”, “an”, and “the” include plural referents unless the contentclearly dictates otherwise. As used in this specification and theappended claims, the term “or” is generally employed in its senseincluding “and/or” unless the content clearly dictates otherwise.

It is noted that references in the specification to “an embodiment”,“some embodiments”, “other embodiments”, etc., indicate that theembodiment described may include one or more particular features,structures, and/or characteristics. However, such recitations do notnecessarily mean that all embodiments include the particular features,structures, and/or characteristics. Additionally, when particularfeatures, structures, and/or characteristics are described in connectionwith one embodiment, it should be understood that such features,structures, and/or characteristics may also be used connection withother embodiments whether or not explicitly described unless clearlystated to the contrary.

The following detailed description should be read with reference to thedrawings in which similar elements in different drawings are numberedthe same. The drawings, which are not necessarily to scale, depictillustrative embodiments and are not intended to limit the scope of theinvention. “Mammal” as used herein refers to any member of the classMammalia, including, without limitation, humans and nonhuman primatessuch as chimpanzees, and other apes and monkey species; farm animalssuch as cattle, sheep, pigs, goats and horses; domestic mammals such asdogs and cats; laboratory animals including rodents such as mice, ratsand guinea pigs, and the like. The term does not denote a particular ageor sex. Thus, adult and newborn subjects, as well as fetuses, whethermale or female, are intended to be included within the scope of thisterm.

The term “cryopreservation”, as used herein, refers to the process ofcooling and storing biological cells, tissues, or organs at lowtemperatures to maintain their viability. As a non-limiting example,cryopreservation can be the technology of cooling and storing cells at atemperature below the freezing point (e.g., −20° C. or colder, −80° C.or colder, or the like) that permits high rates of survivability of thecells upon thawing.

The term “cryoprotectant”, as used herein, refers to a substance that isused to protect biological cells or tissues from the effects offreezing.

As used herein, the term “microbiota” can refer to the human microbiome,the human microbiota, or the human gut microbiota. The human microbiome(or human microbiota) may be understood as the aggregate ofmicroorganisms that reside on the surface and in deep layers of skin, inthe saliva and oral mucosa, in the conjunctiva, and in thegastrointestinal tracts of humans. The human microbiome is comprised ofbacteria, fungi, viruses, and archaea. At least some of these organismsperform tasks that are useful for the human host. Under normalcircumstances, these microorganisms do not cause disease to the humanhost, but instead participate in maintaining health. Hence, thispopulation of organisms is frequently referred to as “normal flora.”

The population of microorganisms living in the human gastrointestinaltract is commonly referred to as “microbial flora”, “gut flora”, and/or“gut microbiota”. The microbial flora of the human gut encompasses awide variety of microorganisms that aid in digestion, the synthesis ofvitamins, and creating enzymes not produced by the human body.

The phrase “microbiota restoration therapy”, as used herein, refers to acomposition which may include, but is not limited to, human fecalmaterial containing viable gut flora from a patient or donor, a diluent,and a cryoprotectant. Additional compositions include equivalentfreeze-dried and reconstituted feces or a “synthetic” fecal composition.The human fecal material is screened for the presence of pathogenicmicroorganisms prior to its use in the microbiota restoration therapy.The human fecal material is screened for the presence of Clostridiumspecies including C. difficile, Norovirus, Adenovirus, entericpathogens, antigens to Giardia species, Cryptosporidia species and otherpathogens, including acid-fast bacteria, enterococci, including but notlimited to vancomycin-resistant enterococci (VRE), methicillin-resistantStaphylococcus aureus (MRSA), as well as any ova or parasitic bodies, orspore-forming parasites, including but not limited to Isospora,Clyslospora, and Cryptospora.

More than 1000 different species of bacteria reside in a healthygastrointestinal (GI) tract. Clostridia are anaerobic, spore-formingbacteria. Certain species of clostridia are pathogens, producing toxinsthat can be harmful to humans. Clostridium difficile (“C diff”) is onespecies of Clostridium that, if overpopulated in the GI tract, canrelease toxins that can cause a number of symptoms, including bloating,constipation, diarrhea, inflammation, abdominal pain, among others that,in certain cases, can lead to death.

When stressed, Clostridium difficile create spores that can tolerateextreme conditions many active bacteria cannot. Generally, clostridia donot compete well in a healthy GI tract. However, antibiotics can disruptthe normal intestinal flora, leading to an overgrowth of Clostridiumdifficile. In certain examples, the Clostridium difficile spores can beresistant to various antibiotics. Thus, as the normal intestinal florais cleared, the Clostridium difficile spores remain, leading to a largepopulation of Clostridium difficile.

According to the Centers for Disease Control and Prevention, (CDC)approximately 337,000 cases of Clostridium difficile infection (CDI) arereported each year in the United States resulting in about 14,000deaths. The current standard of care is antibiotic treatment; typicallywith metronidazole and/or vancomycin. Following initial antimicrobialtreatment, approximately 25% of the patients experience a recurrence insymptoms. In this recurrent patient population, approximately 45-65%developed persistent recurrent CDI. Persistent recurrent CDI isassociated with high morbidity and mortality. For example, estimates ofClostridium difficile overpopulation incidence vary from 1.5 to 2.7million occurrences in the United States per year, and are growing. Inone estimate, hospital discharges with Clostridium difficile doubledfrom 2001 to 2005, with an estimated 5% to 25% compound annual growthrate. Current estimates indicate that patients affected by Clostridiumdifficile overpopulation experience increased hospital stays from 3 to36 days, with nearly 20% of affected patients being readmitted within180 days, each more likely to be discharged to long-term care facilitiesthan patients not affected. The financial impact of Clostridiumdifficile is estimated at $1 to $3 billion annually. Moreover, anestimated 300 patient deaths per day are attributable to Clostridiumdifficile overpopulation, a mortality rate of 1 to 7.7%, and increasing.

Traditional treatment for Clostridium difficile typically includesapplication antibiotics. Metronidazole (“Flagyl®”) is the antibiotic ofchoice due to low price and high efficacy. However, for recurring cases(up to 20% of total cases, for example, resistant to metronidazole),pregnant patients, or patients younger than 10 years of age, vancomycin(“Vancocin®”) is typically used. However, vancomycin, although typicallyhaving fewer side effects than metronidazole, has a much higher cost andmay lead to resistance of existing Clostridium difficile to furtherantibiotics.

At first occurrence, antibiotic treatment for Clostridium difficile canbe acutely effective to treat diarrhea within 2 to 4 days at a rateapproximately at or above 90%. However, Clostridium difficile typicallyrecurs after the first occurrence (e.g., several days to 12 weeks aftercessation of antibiotics) at an estimated 20% rate (e.g., 15%-30%).However, for each recurrence following the first recurrence, the rateincreases greatly, to an estimated 40% rate following the secondrecurrence, and to greater than an estimated 60% rate or greaterthereafter. It is estimated that approximately 5% of patients have 6 ormore recurrences.

Treatment for Clostridium difficile typically varies after eachoccurrence. For example, for first mild to moderate recurrence,metronidazole can be administered orally (e.g., at a dose of 500 mg,three times daily (“TID”) for 10 to 14 days). For a second recurrence,vancomycin can be administered orally in tapered or pulsed doses (e.g.,at a dose of 125 mg, four times daily (“QID”) for 14 days; at a dose of125 mg, twice daily (“BID”) for 7 days; at a dose of 125 mg, once daily(“QD”) for 7 days; at a dose of 125 mg, once every 2 days for 8 days(four doses); at a dose of 125 mg, once every 3 days for 15 days (fivedoses), etc.). For a third recurrence, vancomycin can be applied atgreater doses (e.g., at a dose of 125 mg, four times daily (“QID”) for14 days), combined with any of the other options for recurrentinfection, such as intravenous immunoglobulin (e.g., at a dose of 400 mgper kg body weight, once every three weeks, for a total of two or threedoses depending on effect), or rifamycin following the vancomycin doses(e.g., the rifamycin at a dose of 400 mg, twice daily (“BID”) for 14days), etc.

Fecal transplantation (FT), a treatment related to microbiotarestoration therapy (MRT), has been practiced as a last resort for somepatients having recurrent CDI. Following antimicrobial treatment, FT isused to re-establish a healthy microbial mix in the gastrointestinalmicrobiota of the patient. Over 480 cases have been reported with a ˜90%cumulative success rate in curing recurrent CDI without any adverseevents attributable to the FT material. The current institutionalpractice is to obtain fecal samples from family members or volunteerswithin the treating institution for transplantation into the patient. Anevident problem with this technique of treatment is that the FT materialis not standardized. Although donors are generally selected that areconsidered healthy at the time of donation, this is not adequate toassure both the quality and viability of the microbes to betransplanted. A disease state affecting the fecal material may bepresent that is unknown to the donor. In addition to the quality of theraw fecal material, the lack of a standardized procedure for processingand handling at the receiving or treating institution can lead toproblems with both the quality and viability of the FT material given tothe patient. Further, each institution must handle the raw fecalmaterial, which is undesirable.

There is a need for a standardized, pre-processed MRT product thatassures quality and viability of the MRT product for the patient at thetime of delivery. It is further desirable to have an MRT product whichcan also be shipped to a suitable treatment facility after processing ina readily handled and deliverable state to eliminate handling of rawfecal material at each institution. With these improvements, MRT canbecome a desirable/viable primary treatment option for CDI rather than atreatment of last resort at a small number of institutions.

This document discusses, among other things, receiving a plurality ofdonor fecal samples from a plurality of donors and storing and indexingeach respective donor fecal samples using at least one characteristic ofthe respective donor fecal sample. In an example, the donor fecal samplecan be screened and processed for subsequent use in fecalbacteriotherapy to displace pathogenic or undesired organisms in thedigestive track of a patient with healthy or desirable gut microbiota.

The disclosure provides a microbiota restoration therapy compositioncomprising a mixture of an effective amount of fecal microbiota and aneffective amount of a cryoprotectant. An example cryoprotectant mayinclude polyethylene glycol. Additionally, in the microbiota restorationtherapy composition of the disclosure, the polyethylene glycol ispresent in a concentration from about 5-60 g/ml, or about 5-30 g/ml, orless than about 30 g/ml. The composition can further include saline as adiluent. The compositions of the disclosure may comprise polyethyleneglycol having an average molecular weight ranging from about 600 toabout 20000. For example, PEG-3150, having an average molecular weightof 3150 can be utilized. In certain embodiments, the microbiotarestoration therapy compositions comprise fecal microbiota derived fromone or more human stool samples.

Other cryoprotectants may be used such as dextrose, betaine, glycine,sucrose, polyvinyl alcohol, Pluronic F-127, mannitol, tween 80, ethyleneglycol, 1,3-propanediol, hydroxypropyl cellulose, glycerol, PEG/glycerolmix, milk (e.g., skim milk), and propylene glycol.

In other embodiments, the viability of the microbiota of thecompositions of the disclosure may be confirmed by culturing themicrobiota (and/or the filtrate and/or a bacteriotherapy composition) ona Bacteroides Bile Esculin Agar (BBE) plate (available from Becton,Dickinson and Company, catalog number 221836, BBL™ Bacteroides BileEsculin Agar BBE plate), or a Center for Disease Control (CDC) plate(available from Becton, Dickinson and Company, catalog number 221733,BBL™ CDC Anaerobe 5% Sheep Blood Agar Plates), or both. In at least someembodiments, the viability of the microbiota of the compositions of thedisclosure may be confirmed on a BBE and/or CDC plate by the presence ofa colony forming unit (CFU) count of about 30 CFU to about 300 CFU at aserial dilution of 10⁻⁵, or by the presence of a CFU count of about 30CFU to about 300 CFU at a serial dilution of 10⁻⁶. Further provided aremicrobiota restoration therapy compositions where the concentration ofmicrobiota is on the order of about 10⁷ microbes/ml. Additionally, themethods for producing a microbiota restoration therapy composition mayfurther comprise the steps of conducting both pre- and post-donorscreening with the human stool sample collected in the interval therebetween.

In addition to confirming viability of the microbes, the plating testscan also confirm the diversity of the living microbes present. The mixof microbes present, or diversity of microbes, is a further measure ofthe quality of the human stool sample and the MRT product made from thatsample. The CDC plates and the BBE plates, either alone or incombination provide a measure of quality through diversity as describedherein.

The disclosure also provides methods for assuring the quality of a humanstool sample to be processed into a microbiota restoration therapycomposition, the methods comprising identifying a human stool donor;conducting a pre-donation screening of the donor, comprising a healthhistory questionnaire, a daily diet questionnaire, and at least oneblood test; collecting a human stool sample from the donor; processing athe stool sample from the donor to form one or more microbiotarestoration therapy compositions; conducting a post-donation screeningof the donor at an interval of about 15-120 days, or about 30-100 days,or about 45-90 days, comprising a health history questionnaire and atleast one blood test; holding in quarantine one or more microbiotarestoration therapy compositions processed from the donor stool samplecollected during the interval between pre-donation screening andpost-donation screening; confirming the quality of the microbiotarestoration therapy compositions from both pre- and post-screeningresults; and releasing for the microbiota restoration therapycompositions for use in a human in need of microbiota restorationtherapy. Pre/Post screening may improve the likelihood of collecting ahealthy sample. The interval is selected to allow adequate time for adisease state or other factor that is present at the time of human stoolcollection to manifest with symptoms or be positively identified in ahuman stool or serum test at the post-screening. Further, thecomposition can be quarantined and stored until validation of donorhealth via both the pre- and post-screening is confirmed.

The methods of the disclosure may further include the step of conductingat least one test on the human stool sample for the presence ofinfectious disease. Additionally, the methods of the disclosure mayfurther include the step of testing the human stool sample for aconstituent selected from the group consisting of: C. difficile;Norovirus; Adenovirus; Enteric Pathogens; Giardia antigen;Cryptosporidium antigen; Acid-fast staining (Clyslospora, Isospora); ovaand parasites; Vancomycin-resistant enterococci (VRE);Methicillin-resistant Staphylococcus aureus (MRSA) and combinationsthereof. The methods of the disclosure may include testing the blood ofthe donor, wherein the blood test includes at least one test for aconstituent selected from the group consisting of: HIV; Hepatitis A;Hepatitis B; Hepatitis C; RPR and combinations thereof.

A representative method for producing a microbiota restoration therapycomposition from a human stool sample and assuring viability of thecomposition can include collecting a desired amount of human stoolsample, adding saline, adding a cryoprotectant (e.g., polyethyleneglycol), and mixing the composition. The resultant mixture can then befiltered and the filtrate containing microbes collected. A portion ofthe filtrate can be collected for testing and the remainder of thefiltrate can be frozen as quarantined until testing verifies the qualityof the frozen filtrate based on culturing of the test sample coupledwith results of pre- and post-screening as described above.

The present disclosure is directed to compositions, methods ofmanufacture, and methods of treatment utilizing microbiota restorationtherapy of the gastrointestinal tract by displacing pathogenic and/orineffective organisms with healthy, effective bacterial flora. Exampleconditions and disease states that may be treated include Clostridiumdifficile infection, irritable bowel syndrome (IBS), Crohn's disease,ulcerative colitis (UC), fulminant colitis resulting from astaphylococcus or C. diff infection, inflammatory bowel disease (IBD),ulcers, diabetes, colon cancer, constipation, obesity, and otherconditions and disease states related to an imbalance of the intestinalbacterial flora.

In some examples, compositions, methods of manufacture and methods oftreatment utilizing microbiota restoration therapy (MRT) for thetreatment of Clostridium difficile infections (CDI) are provided. CDI isa common nosocomial infection and is frequently associated with severemorbidity and mortality, especially in elderly patients.

Each individual has a personalized gut microbiota including an estimated500 to 5000 or more species of bacteria, fungi, viruses, archaea andother microorganisms, up to 100 trillion individual organisms, thatreside in the digestive tract, providing a host of useful symbioticfunctions, for example, including aiding in digestion, providingnutrition for the colon, producing vitamins, stimulating the immunesystem, assisting in defense against exogenous bacteria, modulatingenergy metabolism, and the production of short chain fatty acids(SCFAs), specifically, dietary carbohydrates, including resistantstarches and dietary fiber, which are substrates for fermentation thatproduce SCFAs, primarily acetate, propionate, and butyrate, as endproducts. However, an improperly balanced or functioning gut microbiotamay play a role in certain diseases or afflictions, such aspseudomembranous colitis, Clostridium difficile colitis,antibiotic-associated diarrhea (AAD), ulcerative colitis (UC),pouchitis, irritable bowel syndrome (IBS), obesity, among others.

Accordingly, the present inventor has recognized, among other things,systems and methods for providing bacteriotherapy to treat afflictionsassociated with the gut microbiota, including Clostridium difficilecolitis, by displacing pathogenic organisms in the digestive track of apatient with healthy bacterial flora, or bacterial flora intended tobenefit a specific individual with an affliction associated with the gutmicrobiota. In an example, the systems and methods described herein canprovide a convenient, hygienic mechanism, capable of meshing withexisting capabilities and routines of existing clinics and hospitals,for providing bacteriotherapy to a patient. In certain examples, similartreatment can be effective for patients with other diseases, such asIBS, Crohn's disease, ulcerative colitis (UC), inflammatory boweldisease (IBD), ulcers, or other gastrointestinal, metabolic, ordigestive tract related disease. In other examples, bacteriotherapy canbe used to aid in weight loss, displacing ineffective flora in the gutwith a more effective microbiota. In other examples, bacteriotherapy canbe used to aid in cardiovascular and peripheral vascular disease.

In an example, bacteriotherapy to treat Clostridium difficile or one ormore other diseases or afflictions of the digestive tract can beprovided using a combination of antibiotics and re-population of ahealthy or desired mammalian bacterial flora. In certain examples, there-population of bacterial flora can include fecal bacteriotherapy, orfecal transplant.

The process of fecal bacteriotherapy can include introducing a fecalsample of a healthy donor, or a donor having one or more desiredcharacteristics, into a gastrointestinal tract of a patient torepopulate a healthy or desirable gut microbiota. In certain examples,prior to introduction of the fecal sample, the patient's intestinalflora can be disrupted using antibiotics, such that the healthy ordesirable gut microbiota, once introduced into the patient, can easilypopulate the gastrointestinal tract. For example, some of the methodscontemplated herein may include methods for treating a gastrointestinaldisorder that include administering a pre-treatment antibiotic to apatient with a gastrointestinal disorder and administering a microbiotarestoration therapy composition (e.g., the microbiota restorationtherapy compositions as disclosed herein) to the patient. Thepre-treatment antibiotic may include vancomycin, fidaxomicin,rifaximimin, linezolid, daptomycin, quinupristin-dalfopristin,tigecycline, ceftaroline, ceftobiprole, televancin, teicoplanin,dalbavancin, metronidazole, ortivancin, or a combination thereof. Thepre-treatment antibiotic may be administered at a suitable dose (e.g.,about 0.01 mg per day to about 5000 mg per day). In some instances, thepre-treatment antibiotic is administered as a single dose. In otherinstances, two or more doses may be administered. If two or more dosesare administered, the antibiotics used for each of the doses may be thesame or different. In some instances, pre-treatment with an antibioticmay not be necessary or desired. Accordingly, methods are contemplatedthat do not include pre-treatment with an antibiotic (e.g.,pre-treatment is purposefully omitted).

The methods for treating a gastrointestinal disorder may also includeadministering a post-treatment antibiotic to the patient afteradministering the microbiota restoration therapy composition to thepatient. The post-treatment antibiotic may be the same as or differentfrom the pre-treatment antibiotic. In some instances, post-treatmentwith an antibiotic may not be necessary or desired. Accordingly, methodsare contemplated that do not include post-treatment with an antibiotic(e.g., post-treatment is purposefully omitted).

The methods for treating a gastrointestinal disorder may also includeadministering a second dose of the microbiota restoration therapycomposition to the patient. Additional doses may also be administered.Multiple doses of the microbiota restoration therapy composition may beadministered in conjunction with one or more doses of a pre-treatmentantibiotic (e.g., as disclosed herein), in the absence of apre-treatment antibiotic, in conjunction with one or more doses of apost-treatment antibiotic (e.g., as disclosed herein), in the absence ofa post-treatment antibiotic, or the like.

In one example, a single dose of a pre-treatment antibiotic isadministered to the patient and a primary dose of the microbiotarestoration therapy composition is administered to the patient. Thisexample may or may not include administration of one or more doses of apost-treatment antibiotic to the patient.

In another example, a primary dose of a pre-treatment antibiotic isadministered to the patient, a secondary dose of a pre-treatmentantibiotic is administered to the patient, and a primary dose of themicrobiota restoration therapy composition is administered to thepatient. This example may or may not include administration of one ormore doses of a post-treatment antibiotic to the patient.

In another example, a single dose of a pre-treatment antibiotic isadministered to the patient, a primary dose of the microbiotarestoration therapy composition is administered to the patient, and asecondary dose of the microbiota restoration therapy composition isadministered to the patient. This example may or may not includeadministration of one or more doses of a post-treatment antibiotic tothe patient.

In another example, a primary dose of a pre-treatment antibiotic isadministered to the patient, a secondary dose of a pre-treatmentantibiotic is administered to the patient, a primary dose of themicrobiota restoration therapy composition is administered to thepatient, and a secondary dose of the microbiota restoration therapycomposition is administered to the patient. This example may or may notinclude administration of one or more doses of a post-treatmentantibiotic to the patient.

In another example, a primary dose of the microbiota restoration therapycomposition is administered to the patient in the absence ofadministering a pre-treatment antibiotic to the patient. This examplemay or may not include administration of one or more doses of apost-treatment antibiotic to the patient.

In another example, a primary dose of the microbiota restoration therapycomposition is administered to the patient and a secondary dose of themicrobiota restoration therapy composition is administered to thepatient. The primary and secondary doses of the microbiota restorationtherapy composition are administered in the absence of administering apre-treatment antibiotic to the patient. This example may or may notinclude administration of one or more doses of a post-treatmentantibiotic to the patient.

Administering the antibiotics and/or the microbiota restoration therapycompositions to the patient may include suitable routes ofadministration including those disclosed herein (e.g., orally, by enema,by suppository, or the like).

The human fecal material is optionally filtered prior to its use in themicrobiota restoration therapy.

In an example of treating a gastrointestinal disorder, a firstmicrobiota restoration therapy composition may be administered to apatient, the first microbiota restoration therapy composition derivedfrom a unique donor. A need for further treatment may be ascertained,and a second microbiota restoration therapy composition that is derivedfrom the same unique donor may be administered to the patient. In somecases, the first microbiota therapy composition comprises a mixture offecal microbiota and polyethylene glycol.

In an example, administering the first microbiota restoration therapycomposition to a patient includes administering one or more doses of thefirst microbiota restoration therapy composition. In some cases,administering a second microbiota restoration therapy composition to apatient includes administering one or more doses of the secondmicrobiota restoration therapy composition. In an example, apre-treatment antibiotic may be administered to the patient. In somecases, a post-treatment antibiotic may be administered to the patient.In some cases, administering a first microbiota restoration therapycomposition to a patient includes administering an enema. In someinstances, administering a second microbiota restoration therapycomposition to a patient includes administering an enema. In an example,ascertaining a need for further treatment includes recognizing that thepatient is still suffering from the gastrointestinal disorder such as aC. difficile infection.

Another example of treating a gastrointestinal disorder includesadministering a pre-treatment antibiotic to a patient with agastrointestinal disorder. A primary dosage of a microbiota restorationtherapy composition may be administered to a patient. A need for furthertreatment may be ascertained and a secondary dosage of the samemicrobiota restoration therapy composition may be administered to thepatient. In some cases, the microbiota restoration therapy compositionis derived from a single donor.

In an example, the pre-treatment antibiotic includes vancomycin,fidaxomicin, rifaximimin, linezolid, daptomycin,quinupristin-dalfopristin, tigecycline, ceftaroline, ceftobiprole,televancin, teicoplanin, dalbavancin, metronidazole, ortivancin, or acombination thereof. Optionally, a post-treatment antibiotic may beadministered, and may be the same or different from the pre-treatmentantibiotic.

In an example, the microbiota restoration therapy composition ismanufactured by collecting a human fecal sample and adding polyethyleneglycol to the human fecal sample to form a diluted sample. The dilutedsample is mixed with a mixing apparatus and is filtered to form afiltrate. The filtrate may be transferred to a sample bag which is thensealed.

In some cases, administering the first dosage of the microbiotarestoration therapy composition to a patient includes administering oneor more distinct doses of the microbiota restoration therapycomposition. In some instances, administering the second dosage of themicrobiota restoration therapy composition to a patient includesadministering one or more distinct doses of the microbiota restorationtherapy composition.

An example of treating a gastrointestinal disorder includesadministering a pre-treatment antibiotic to a patient with agastrointestinal disorder. A primary dosage of a microbiota restorationtherapy composition derived from a unique donor may be administered to apatient, the microbiota restoration therapy composition pre-screened forbacterial diversity. A need for further treatment may be ascertained anda secondary dosage of the microbiota restoration therapy compositionderived from the unique donor may be administered to the patient. Insome cases, the microbiota restoration therapy composition includesbacterial from at least seven different families and has a ShannonDiversity Index of 0.4-2.5 when calculated at the family level and maybe administered with an enema tube.

In some embodiments of the present disclosure, the composition is astandardized fecal microbial preparation from pre-screened donors.Donors are screened for common infectious diseases in both serum andhuman stool. This includes laboratory testing as well as review of thedonor's medical history. Once the donor has been qualified, he/she willbe required to undergo complete re-screening at selected intervals. Thiscan include a period of each one to three month period, with one exampleinterval of approximately every three months. In some methods of asystem for collecting quality or normal fecal material, in between thecomplete re-screenings, donors will be instructed to contact the samplecollector immediately if changes to their health status occur. Furtherthis health information can be collected at the time of every donationbetween complete screenings via questionnaire or other means. The donorcan continue to be a qualified donor as long as he/she continues to passtheir screening tests and meet the health status requirements.

Collected human stool can be processed as disclosed herein, then frozenand quarantined. The product can be released from quarantine when bothpre-collection and post-collection medical screening (for example, humanstool and blood tests along with health status) is completed. Thisassures the quality of the sample collected between screenings. Theproduct can be thawed and shipped in a temperature-controlled containerto the institution or alternatively shipped frozen and thawed at theinstitution.

The present composition is particularly suited for patients havingrecurrent CDI. Recurrent CDI is defined as a patient who has had aminimum of at least one recurrent episode after the primary episode, andwill have completed at least two courses of oral antibiotics to treattheir CDI. The composition is also suited for treatment of a primaryepisode of CDI.

In one method of treatment in the present MRT, a patient can complete a10-14 day course of oral antibiotics, including at least 7 days ofvancomycin at the end of the regimen, followed by a 24-48 hour washoutperiod. The MRT composition can then be introduced via enema. Thetreatment can be considered successful if there is resolution of CDIsymptoms at 60 days after administration of the first enema. In somepatients, a second enema with the MRT composition can be administered ifsymptoms return within the 60 day period and successful treatment can benon-recurrence of symptoms within 60 days following the second enema.

Human fecal material is by nature variable between donors and evenvaries from day-to-day in the same donor. Further, an individual sampleof human fecal material has more than 1000 different microbes present atany time making it not feasible to test and delineate the entire fecalmicrobiome in a sample and even less feasible to determine the effect ofindividual species of microbes on a given disease, such as CDI. However,with the present disclosure, it has been found that a standardized ornormal sample of fecal material can be identified and processed to a MRTcomposition or MRT product that assures safety and viability. With avariable raw material, the present composition is made using donorscreening methods, fecal testing methods, fecal processing methods,processed material handling, storage and preservation methods, andtesting methods to produce a consistent, reproducible,quality-controlled composition from human feces to be delivered as atherapeutic product for treating various conditions and disease statesaffected by microbial imbalance within the GI tract.

The present composition can begin with what is characterized as a normalhuman stool sample. In order to define a normal human stool sample thepatient can be screened via questionnaire or other health history meanscoupled with blood and/or human stool testing to confirm or check othercharacteristics. Further, the human stool sample can be handled andprocessed in a controlled manner with the resultant product tested toconfirm both that the human stool sample was normal and that theprocessing and handling has been completed in a way that maintains theviability of the microbes in the product composition. In addition toviability, selected testing can be performed to affirm the diversity ofviable microbes present, another measure of healthy or normal stool. Inthis way, donor to donor variation and within donor day-to-day variationcan be understood and utilized in the criteria for a normal human stoolsample. Further, the validity of the processing and handling techniquesas designed and implemented can be confirmed. The combination ofcollecting a normal human stool and using validated processing andhandling techniques results in a standardized composition or product.Once a standardized composition is made, it must be stored and handledfrom production to administration in a way that maintains the viabilityof the product to assure successful treatment. A validated process whichmaintains viability of the standardized product from the time ofproduction through administration to the patient is critical tosuccessful treatment. It will be appreciated that during the processingof samples, the encapsulation of such extracts to produce medicaments ofthe disclosure, it may generally be desirable to track a sample toensure that that the medicaments produced are tracked, stored and bankedappropriately for later processing, handling and use. In order tofacilitate such tracking it may be desirable that suitable tags be usedto identify a sample, extract and medicine, and allow these to beassociated with one another, and with the patient to be treated. Thismay be achieved by the use of RFID tags or DNA analysis of donorsamples. One skilled in the art would be familiar with other tagssuitable for tracking medicaments of the disclosure, for example barcodes.

In characterizing the human stool sample to determine whether it isnormal or within the range considered normal, health history data, serumand/or blood analysis and human stool analysis can be utilized.Additionally, a constant set of processing parameters can be utilized toproduce a product that can be cultured on selected media to determinethe presence of viable select microbes and groups of microbes to confirmviability and diversity within the human stool sample. The processingparameters can also be utilized to produce a product that can becultured on selected media to determine the absence of certain microbesand/or groups of microbes. This part of the processing protocol can beused to confirm safety of the stool sample for use in the MRT product.

The handling and processing of the human stool sample to a standardizedand viable MRT product can include consistent and proven collection andhandling techniques, filtering processes, controlled homogenization andaddition of select liquids and amounts of these liquids. Further, thecomposition produced, which is the standardized composition or product,by this controlled and proven handling and processing, can be culturedon selected media to determine the presence of viable select microbesand groups of microbes to confirm the viability and microbe diversity inthe product.

From the time of producing the standardized product through the time ofadministration to the patient, the standardized product must bemaintained viable for successful treatment. This can include using afrozen storage technique and cryoprotectant to maintain viability. Inparticular, Applicants have discovered that polyethylene glycol (PEG)can be used as an effective cryoprotectant for MRT products. Time ofstorage, thawing technique, shipping technique and handling of thethawed product are also factors that affect viability and are definedherein. The techniques defined herein can be used from the time thestool donation is received through the production of the standardizedproduct and through the administration to the patient. The techniquesprovided herein also allow for viability of the microbiota in the MRTproduct to be maintained and confirmed. Provided are protocols forconfirming the presence, viability and diversity of select microbes andgroups of microbes by culturing on selected media. Further, thetechniques provided herein can be used to confirm the presence,viability and diversity of select microbes and groups of microbes at anypoint during the process, from collection to processing to production tostorage to post-thaw to just prior to administration to a patient and atevery point in between. In one embodiment, the cryoprotectantpolyethylene glycol (PEG) can be mixed with the human stool sample andisotonic saline at the time of processing. PEG can be added at aconcentration from about 0.1 g/ml. to about 70 g/ml, or from about 2g/ml to about 68 g/ml, or from about 4 g/ml to about 65 g/ml, or fromabout 5 g/ml to about 60 g/ml. The PEG used can have an averagemolecular weight of about 600 to about 20000. In some embodiments, thePEG has an average molecular weight of about 2000 to about 4000, forexample about 3350 as provided in the formulation of PEG 3350.

The growing of cultures to define normal human stool sample can includethe following techniques, recognizing that the raw human stool cannot beconsistently cultured. A processed sample product was made using a 50gram (g) human stool sample and mixed under consistent conditions with aratio of about 2 to about 4 mL of a PEG/saline mixture to 1 g of humanstool in a sterile mixing/filter bag to create a bacterial suspension.In some embodiments, the bacterial suspension is filtered, according tostandard techniques, prior to culturing. Plating and incubation of thebacterial suspension was done on growth media as described herein below,and was done according to industry standard anaerobic culture methods.Resulting colony forming units (CFU) were counted, and consistentresults were achieved using these protocols.

Two culturing media are used to culture the bacterial suspension. Thefirst is the Center for Disease Control (CDC) plate, commonly referredto as “CDC Anaerobe 5% Sheep Blood Agar plate. This plate is a generalanaerobic microbe plate, which allows for the isolation and cultivationof fastidious and slow-growing obligately anaerobic bacteria. The secondis the Bacteroides Bile Esculin Agar (BBE) plate, which is a specificindicator species media for Bacteroides. Both types of media arecommonly available for purchase through laboratory suppliers, such asBecton, Dickinson and Co., and Fisher Scientific, for example.

By culturing on selected media, Applicants are able to provide a measureof the diversity of microbes present in the human stool, the productproduced and the product being administered. The techniques disclosedabove can be used to provide a measure of the diversity of the microbesin a human stool sample at any stage. In particular, the CDC plates aredesigned to grow 5 to 7 different families of microbes that can bepresent in the MRT materials. In one non-limiting example, a CDC platecultured with a bacterial suspension must have at least 3 identifiablegenera of microbes growing thereon in order for the bacterial suspensionto be processed and/or used for MRT therapy. Further, the use of the BBEplate can provide an additional measure of microbial diversity in theMRT product. The BBE plate grows multiple species within the Bacteroidesgenus of microbes. Sufficient CFUs on the BBE plates indicate thediversity within the genus present in the MRT product. In certainembodiments, the CDC plate or the BBE plate can be used alone as ameasure of diversity. In other embodiments, both the CDC plate and theBBE plate can be used together to provide an enhanced measure ofdiversity at the microbe genus level, as well as at the species levelwithin a particular microbe genus.

FIG. 1 is a flow chart depicting a portion of an example MRT productionprocess. More particularly, FIG. 1 schematically depicts a process forcollecting and inspecting a donor fecal sample. As a first step in thecollecting/inspecting process, potential stool donors are screened.Screening/prescreening is described in more detail herein. Once thedonor passes the screening, step two may include collecting the donor'sstool using a human stool collection kit as defined herein, whether athome or at a collection facility. The kit can include, but is notlimited to, a clean human stool collection container with lid, a largecloseable/sealable bag, a donation form and a human stool collectioninstruction sheet. The time and date of collection, along with donoridentity and method of transport, can be recorded in order to track thetime from collection to processing, and the conditions of transport. Asa non-limiting example, the collection container can include anindicator of the minimum and the maximum temperature to which the sampleis exposed. As another non-limiting example, one or more temperaturesensitive stickers that changes color at temperatures below about 4° C.and temperatures greater than about room temperature (about 22-29° C.)can be affixed to the container.

Step three may involve transporting the sample to a processing facility.It can be appreciated that if the sample is collected at the processingfacility, transporting the sample is not necessary. In some instances itmay be desirable to collect the sample at the processing facility inorder to more clearly establish the chain of custody of the sample. Withthe receipt of the first stool donation for any individual, a profilewill be established for each donor. Subsequent stool samples can besubjected to a human stool test, which is utilized to match and confirmthe identity of the donor with the donation. Based on prior collectedsamples, a human stool profile for the donor is generated and can bemaintained or enhanced over repeated donations. Any new sample will becompared with this profile to confirm it is the same donor.Differentiation can be made to confirm donor identity based on therepresentation of Bacterioides species in the human stool. In anon-limiting example, the base set of stool samples used to create theprofile is collected at the processing facility to assure donor identityin the profile samples. In another non-limiting example, the base set ofstool samples used to create the profile can be collected in locationsother than the processing facility, with donor identity assuranceprotocols appropriate to the situation or location.

Step four of the method may include labeling the donation “Quarantine”and holding the donation in quarantine at or below room temperature forno longer than 24 hours prior to processing. Donations may be rejectedin situations where the temperature indicator has been activated orwhere the time between donation and receipt exceeds 24 hours. Inaddition, where applicable, the human stool test results must match thedonor profile. If the human stool test does not match the donor profile,the donation collected for that day will be discarded and the donor willbe disqualified.

In one method of the disclosure, the human stool sample is processedwithin about 24 hours of collection. In another method of theapplication, the time of collection is recorded at the time of arrivalof the stool sample at the processing facility. Step six may includeinspecting the stool donation. Visual inspection can be completed uponarrival of the stool sample at the processing facility. In the event thehuman stool sample is loose, unformed, is not of sufficient weight(e.g., less than about 50 g), or for any other reason, including but notlimited to evidence indicating poor sample quality or concerns aboutdonor health, the sample may be rejected, labeled “Inspection—Rejected”and the donation is discarded. Further, answers to questions on thehuman stool collection form can be reviewed by trained personnel.Certain answers in the collection form may require ample rejection. Ifthe sample is accepted, it may be labeled “Inspection—Accepted” and maybe moved to a manufacturing process.

Another example method of screening donors, obtaining human stoolsamples, and processing the stool samples to a MRT product isillustrated in the flow chart depicted in FIG. 2. Step one may includeenlisting potential donors. Step two may include having the potentialdonors complete an Initial Donor Health History Questionnaire (IDHHQ).The questionnaire may be similar to that used by the Red Cross forscreen of potential blood donors (with potentially additional screeningquestions, if desired). A result of “fail” causes the potential donor tobe rejected and removed from the donor pool. For example, a donor willreceive a “fail” result under conditions similar to what would cause apotential donor to fail a Red Cross screen. A result of “pass” causesthe donor to be accepted for further testing. Step four may involvefurther testing and review which, if the donor fails, removes the donorfrom the pool. Donors are regularly screened for common infectiousdiseases and other conditions as listed herein. A review of the donor'smedical history by trained personnel, and repeat screening tests, willbe conducted at regular intervals, such as, but not limited to,approximately every 15-90 days. Screening can include the constituentslisted in Table 1, below.

TABLE 1 Donor Screening Tests Test Name Material Tested AcceptanceCriteria C. difficile B via PCR and GDH Stool Negative for C. difficileGDH result is not a pass/fail criterion - for information only Norovirusvia PCR Stool Negative Rotovirus via PCR Stool Negative Adenovirus viaPCR Stool Negative Enteric Pathogens (Shigella, Stool Negative forShigella, Salmonella, Campylobactoer, Salmonella, Camphylobacter,sorbitol-negative E. coli., sorbitol-negative E. coli., Aeromonas,Yersinia, Aeromonas, Yersinia, and Plesiomonas, Shiga toxins)Plesiomonas. No Shiga toxins detected Giardia Antigen Stool NegativeCryptosporidium Antigen Stool Negative Acid-fast Staining (Clyslospora,Stool Negative Isospora) Ova and Parasites Stool Nodetection/identification of: Giardia, Entamoeba histolytica (amoeba),Helminth eggs, protozoa, larval worms and segments Vancomycin-resistantStool No VRE isolated enterococci (VRE) Methicillin-resistant Stool NoMRSA isolated Staphylococcus aureus (MRSA) Vibrio Stool Non-reactiveListeria Blood (Serum) Negative Human Immunodeficiiency Virus Blood(Serum) Non-reactive (HIV) Hepatitis A (IgG); must be + or Blood (Serum)Non-reactive else be vaccinated Hepatitis B: Anti-Hepatitis B Blood(Serum) Non-reactive surface antigen must be + or else be vaccinatedHepatitis C Antibody Blood (Serum) Non-reactive Treponema Antibody Blood(Serum) NegativeThese are just examples. Other tests may also be utilized.

Step five may involve accepting a passing donor into the donor pool, andstep six may involve supplying the donor with a stool collection kit.Step seven may involve starting a schedule of regular collections ofstool samples from the accepted donor, and step eight may involvemanufacturing a drug product from the collected stool samples. Step ninemay involve quarantining the drug product, and step ten may involverescreening the donor stool sample at 45 days. If the sample fails thescreening, all drug product produced from that donor over the past 45days is discarded. If the sample passes the screening, the drug productis released from quarantine (step 11).

In another exemplary method, a human stool sample is weighed and 45 to75 g of the sample is transferred into a sterile filter bag. A mixtureof saline and a cryoprotectant (e.g., polyethylene glycol (PEG) 3350) isused as a diluent, and thus can be added to the human stool sample. Asused herein, the terms “saline/PEG mixture” and “diluent” areinterchangeable. The PEG concentration of the diluent can beapproximately about 30-90 g/liter. The PEG concentration of the diluentcan also be approximately between about 25-75 g/liter. In one example,the ratio of saline/PEG mixture to stool sample is 2:1, or 2 mLsaline/PEG mixture to 1 gram human stool. As a non-limiting example,approximately 100 mL of saline/PEG mixture can be used for 50 g of humanstool. While saline/PEG may be suitable for use as a diluent (and/orcryoprotectant), this is not intended to be limiting. Othercryoprotectants may also be utilized. For example, dextrose, betaine,glycine, sucrose, polyvinyl alcohol, Pluronic F-127, mannitol, tween 80,ethylene glycol, 1,3-propanediol, hydroxypropyl cellulose, glycerol,PEG/glycerol mix, propylene glycol, or combinations thereof may be usedas cryoprotectants. These materials may be used alone or in combinationwith a solvent such as saline.

Once the diluent is added to the bag containing the human stool sample,the bag is sealed. Using a paddle mixer, the stool sample is mixed withthe diluent. The product of the mixed stool sample and diluent isreferred to as a bacterial preparation.

The bacterial preparation can be filtered according to standardtechniques and the filtrate can be removed from the mixing bag andtransferred into sterile pouches or bags. In some embodiments, thebacterial preparation is not filtered.

In other embodiments, each bag containing the bacterial preparation(filtered or not filtered) is the equivalent of one dose of MRT productand is treated as one dose of MRT. In other embodiments, the bags may bestored according to proper protocol and aliquoted into smaller amountsat a later date. In still other embodiments, the bags may be storedaccording to proper protocol, and combined to make one or more doses.Additionally, one or more of the bags of the bacterial preparation canbe retained for Quality Control (QC).

In one non-limiting example, the bags can be labeled with the productnumber and frozen. Once this occurs, the bags may be considered doses ofMRT product. The product number can include reference to the donor IDand date of manufacture (date of processing). The MRT product can befrozen at about −20° C. to about −80° C. or colder. The MRT product canthen be quarantined until the evaluation of the results from the QC testand the additional tests, as described below.

In another non-limiting example, the bags can be labeled with theproduct number and frozen. The product number can include reference tothe donor ID and date of manufacture (date of processing). These labeledbags can be frozen at about −20° C. to about −80° C. or colder (e.g., ascold as about −192° C. as may be accomplished by freezing under liquidnitrogen, if desired). The contents of the bags can then be quarantineduntil the evaluation of the results from the QC test and the additionaltests, as described below.

In one exemplary test of the quality of the manufactured MRT product(including the viability of the microbes as processed), a fecal donationor stool sample collected from a single qualified donor on a single daycan be processed. In some embodiments, no pooling of samples betweendonors or between samples of an individual donor will be done. In otherembodiments, sample preparations from an individual donor are pooled orcombined. In other embodiments, sample preparations from more than onedonor are combined.

A sample of the processed human stool or the MRT product can be diluted,plated, incubated and counted according to standard industry procedures.Anaerobic CFU can be counted on a CDC plate and Bacteroides CFU can becounted on a BBE plate. Plate counts will be checked against the QualityControl standards, which can include, but are not limited to, testingresults from prior donations for the particular donor and otherestablished, appropriate standards. If the counts are within theacceptable range, the MRT product will be considered acceptable. If thecounts are not within the acceptable range, all bags of the MRT productmade from the same human stool sample will be removed from the freezerand destroyed. Final acceptable count ranges can be between about 30 toabout 300 CFU at a serial dilution level of 10⁻⁶ on the CDC plates andabout 30 to about 300 CFU at a serial dilution level of 10⁻⁵ on the BBEplates, prior to freezing of the sample preparation or MRT product.

An exemplary method of processing a drug substance (MRT composition)from release from quarantine to shipment to a customer is shown in FIGS.3A and 3B. Step one may include releasing a drug substance fromquarantine, and step two may include moving the collection container toa Level II BioSafety cabinet. Step three may include taring a filter bagon a bag holder in the BioSafety cabinet on a calibrated scale, followedby weighing about 50 g±10 g of the drug substance into the filter bag instep four. Step five may include adding 3 mL/g of premixed PEG/salinesolution to the drug substance in the filter bag. The premixedPEG/saline solution may be prepared in step A by reconstituting PEGpowder at a concentration of 30 g/L in 0.9% sodium chloride irrigationUSP. Step six may include sealing the loaded filter bag into a closurebag and sealing the closure bag. Step seven may include removing thesealed bag assembly from the BioSafety cabinet and putting the bag intoa paddle mixer. In step eight the bag may be mixed in the paddle mixerat 230 rpm for 2 minutes, following by removing the bag from the paddlemixer and returning the bag to the BioSafety cabinet in step nine. Instep ten, 150 mL of the filtered suspension may be pipetted into anethylene vinyl acetate (EVA) enema bag, followed by sealing the enemabag in step eleven. A sample from the filtered suspension may be setaside for product quality testing. In step B1, CDC and BBE plates may beprepared. Step B2 may include creating serial dilutions from theremaining filtered suspension. This step is performed once per batch. Instep B3 the CDC and BBE plates are inoculated with the serial dilutionsand incubated for 48 hours at 37° C. In step B4 the colony forming units(CFU) per plate are counted.

The exemplary method is continued in FIG. 3B. In step thirteen, the drugproduct sealed in an EVA enema bag may pre-cooled at 0° C. for 60minutes. In step fourteen the EVA bag may be placed in an −80° C.freezer in quarantine until results are received from step B and donortesting. If the drug product fails the testing, all of the affecteddoses of the drug product are discarded. If the drug product passes thetesting, the EVA bag may be moved, in step fifteen, from quarantine to along term storage area of the −80° C. freezer. While the drug product isstored in the −80° C. freezer, an order may be received from a customer.In step sixteen, the EVA bag may be removed from the freezer and thawedto 0° C. for 60 minutes. In step seventeen, the EVA bag may be inspectedfor leaks. If the bag fails the inspection, the product is discarded,and if the bag passes the inspection, the EVA bag is packaged in step 18and shipped to the customer.

FIG. 4 summarizes one example of a delivery method in a flow chart. Acustomer or site order of an MRT product triggers a released product tobe pulled from long term storage at −80° C. The site may be a doctor'soffice, clinic, hospital, or other location where the MRT product is tobe used. The product is thawed and labeled. Quality control (QC) of thelabeling process is performed, with a failure of the labeling processcausing the product to be re-labeled and again passed through qualitycontrol. Passing QC moves the product to the packaging stage where theproduct is packaged into shipping boxes and then shipped to the site.

FIG. 5 summarizes another example of a delivery method in a flow chart.The product is ordered, received, and inspected. Failure of the productto pass inspection causes the product to be discarded, a report to besent to the processing center, and a re-order of product to be placed.If the product passes the inspection, a report is sent to the processingcenter, and the product is either taken to the patient for treatment orstored in a secured location prior to being taken to the patient fortreatment. In either case, the primary packaging is discarded after theproduct is given to the patient.

An example packaging system 10 is shown in FIG. 6. Packaging system 10may include a sample bag 12. Sample bag 12 may be used to contain an MRTcomposition as described herein, a protective inner box 14, a tubeassembly 16, a package 18 (e.g., TYVEK®) for tube assembly 16, a shelfbox 20 (which will house sample bag 12, protective inner box 14, tubeassembly 16 within package 18, and instructions). Shelf box 20 may beplaced in an insulated shipping box 22 (e.g., which may includeStyrofoam) along with ice packs and shipping box 22 may be transportedto a treatment facility. Shipping box 22 may be closed and taped shut inan H-pattern to limit the exchange of air between packaging system 10and the outside atmosphere.

Packaging system 10 was then subjected to a varying range oftemperatures over an extended time period. The testing conditionsincluded removal of sample bag 12 from a thaw bath (e.g., at 0±0.5° C.),placing packaging system 10 in a “cold” environment (e.g., −20±3° C. for4 h±30 min), holding packing system 10 at room temperature for a firsttime period (22±3° C. for 8 h±30 min), placing packaging system 10 in a“hot” environment (50±3° C. for 4 h±30 min), holding packing system 10at room temperature for a second time period (22±3° C. for 8 h±30 min),placing packaging system 10 in a “warm” environment (35±3° C. for 4 h±30min), and holding packing system 10 at room temperature for a third timeperiod (22±3° C. for 8 h±30 min). Under these conditions, thetemperature of sample bag 12 remained below 20° C. for the entire period(approximately 36 hours). According to these test results, packagingsystem 10 provides suitable protection to sample bag 12 from climaticextremes anticipated for the delivery of the MRT compositions disclosedherein.

FIG. 7 illustrates sample bag 12. Bag 12 may be formed from ethyl vinylacetate. Other materials are contemplated. For example, bag 12 mayinclude a polyethylene terephthalate polyester film, a materialsubstantially impervious to gases, other polymers, or the like. Bag 12may resemble an intravenous bag, and optionally bag 12 may include anattachment that will allow bag 12 to be hung on a stand, (e.g., to bepositioned/hung above an endoscope).

Bag 12 may have a capacity in the range of about 25-250 ml (e.g., 50ml). Bag 12 may have a fill port 24 for transporting the MRT compositioninto bag 12. Fill port 24 may include a luer or other type of adapter tofacilitate transportation of the MRT composition. After filling bag 12with the MRT composition, fill port 24 may be sealed, effectivelysealing the MRT composition within bag 12. Bag 12 may also include aspike port 26. Spike port 26 may be utilized to extract the MRTcomposition from bag 12 at the time of use.

FIG. 8 illustrates tube assembly 16. Tube assembly 16 may include aspike member 28 that is designed to piece spike port 26 on bag 12. Tubeassembly 16 may also include a tube body 30 with a step adapter 32. Stepadapter 32 may allow tube 16 to be coupled with a delivery tube 34.

Tube assembly 16 may include a number of additional features. Forexample, a clamp 36 may be coupled to delivery tube 34. In addition, avisual marker 38 may also be disposed along delivery tube 34. A spikecover 40 may be disposed along spike member 28.

The MRT compositions disclosed herein are designed to remain stable overextended periods of time at various temperature conditions. For example,when stored at temperatures of approximately 20-25° C., the MRTcompositions may remain stable (e.g., with a viable population ofmicrobes) for about 24 hours or more, for about 48 hours or more, forabout 96 hours or more, or for about 192 hours or more. When stored attemperatures of approximately 4° C., the MRT compositions may remainstable (e.g., with a viable population of microbes) for about 24 hoursor more, for about 48 hours or more, for about 96 hours or more, forabout 192 hours or more, or for about 240 hours or more. In other words,the “thawed shelf life” of the MRT compositions may be on the order ofabout 24 hours or more, about 48 hours or more, about 96 hours or more,about 192 hours or more, or about 240 hours or more.

When stored at temperatures of approximately −20° C., the MRTcompositions may remain stable (e.g., with a viable population ofmicrobes) for about 60-90 days or more, for about 4-6 months or more, orfor about 6-9 months or more. When stored at temperatures ofapproximately −80° C., the MRT compositions may remain stable (e.g.,with a viable population of microbes) for about 60-90 days or more, forabout 4-6 months or more, for about 6-9 months or more, or for about 12months or more. In other words, the “frozen shelf life” of the MRTcompositions may be on the order of about 60-90 days or more, about 4-6months or more, about 6-9 months or more, or about 12 months or more.

The MRT compositions of the present disclosure may include bacteria thatare members of at least 1 phylum, at least 2 phyla, at least 3 phyla, atleast 4 phyla, at least 5 phyla, at least 6 phyla, at least 7 phyla, atleast 8 phyla, at least 9 phyla, or at least 10 phyla. In at least someembodiments, the MRT compositions of the present disclosure may includebacteria that are members of at least 1 class, at least 2 classes, atleast 3 classes, at least 4 classes, at least 5 classes, at least 6classes, or at least 7 classes. In at least some embodiments, the MRTcompositions of the present disclosure may include bacteria that aremembers of at least 1 order, at least 2 orders, at least 3 orders, atleast 4 orders, at least 5 orders, at least 6 orders, or at least 7orders. In at least some embodiments, the MRT compositions of thepresent disclosure may include bacteria that are members of at least 1family, at least 2 families, at least 3 families, at least 4 families,at least 5 families, at least 6 families, at least 7 families. In atleast some embodiments, the MRT compositions of the present disclosuremay include bacteria that are members of at least 5, at least 10, atleast 20, or at least 30 different genera of bacteria. In at least someembodiments, the MRT compositions of the present disclosure may includeat least 10, at least 50, at least 100, at least 200, at least 300, orat least 400 different species of bacteria.

For example, the MRT compositions may include viable bacteria from 1 ormore orders or 2 or more orders including, but not limited to,Bacteroidales and Clostridiales. In some embodiments, about 20-95%, orabout 30-85%, or about 40-60% of the viable bacterial in the MRTcompositions may be from the order Bacteroidales. In some of these andin other embodiments, about 10-85%, or about 20-60%, or about 30-40% ofthe viable bacterial in the MRT compositions may be from the orderClostridiales.

In addition or alternatively, the MRT compositions may include bacteriafrom 5 or more families, or about 6-12 families, or about 7-10 families.This may include bacteria from the familes Bacteroidaceae,Burkholderiales, Clostridiaceae, Clostridiales, Eubacteriaceae,Firmicutes, Lachnospiraceae, Porphyromonadaceae, Prevotellaceae,Rikenellaceae, Ruminococcaceae, and Streptococcaceae. In someembodiments, about 20-84%, or about 30-50%, or about 36-48% of theviable bacterial in the MRT compositions may be from the familyBacteroidaceae. In some of these and in other embodiments, about 0.5-2%or about 1% of the viable bacterial in the MRT compositions may be fromthe family Burkholderiales. In some of these and in other embodiments,about 1-10%, or about 1-8%, or about 2-7% of the viable bacterial in theMRT compositions may be from the family Clostridiaceae. In some of theseand in other embodiments, about 1-22%, or about 3-22%, or about 1-10%,or about 1-8%, or about 4-7% of the viable bacterial in the MRTcompositions may be from the family Clostridiales. In some of these andin other embodiments, about 1-10%, or about 1-9%, or about 4-8% of theviable bacterial in the MRT compositions may be from the familyEubacteriaceae. In some of these and in other embodiments, about 0.5-2%or about 1% of the viable bacterial in the MRT compositions may be fromthe family Firmicutes. In some of these and in other embodiments, about0.5-23%, or about 1-10%, or about 4-9% of the viable bacterial in theMRT compositions may be from the family Lachnospiraceae. In some ofthese and in other embodiments, about 0.5-8%, or about 1-5%, or about1-3% of the viable bacterial in the MRT compositions may be from thefamily Porphyromonadaceae. In some of these and in other embodiments,about 0.5-2% or about 1% of the viable bacterial in the MRT compositionsmay be from the family Prevotellaceae. In some of these and in otherembodiments, about 1-30%, or about 1-52%, or about 4-23% of the viablebacterial in the MRT compositions may be from the family Rikenellaceae.In some of these and in other embodiments, about 5-30%, or about 8-25%,or about 10-18% of the viable bacterial in the MRT compositions may befrom the family Ruminococcaceae. In some of these and in otherembodiments, about 0.5-2% or about 1% of the viable bacterial in the MRTcompositions may be from the family Streptococcaceae.

The MRT compositions of the present disclosure may have a ShannonDiversity Index of about 0.4-2.5, or about 1.0-2.0, or about 1.08-1.89,or about 1.25-1.75. These numbers are calculated at the “family” level.Doing calculations at other levels (e.g., phyla, species, etc.) wouldresult in different numbers (e.g., 1-8 or so). Therefore, the ShannonDiversity Index may be on the order of about 1-8 when calculated at thephyla, species, or other levels.

An MRT composition of the present disclosure may be administered by amethod suitable for depositing in the gastrointestinal tract, preferablythe colon, of a subject (e.g., human, mammal, animal, etc.). Examples ofroutes of administration include rectal administration by colonoscopy,suppository, enema, upper endoscopy, upper push enteroscopy.Additionally, intubation through the nose or the mouth by nasogastrictube, nasoenteric tube, or nasal jejunal tube may be utilized. Oraladministration by a solid such as a pill, tablet, a suspension, a gel, ageltab, a semisolid, a tablet, a sachet, a lozenge or a capsule ormicrocapsule, or as an enteral formulation, or re-formulated for finaldelivery as a liquid, a suspension, a gel, a geltab, a semisolid, atablet, a sachet, a lozenge or a capsule, or as an enteral formulationmay be utilized as well. Compositions may be treated or untreated fecalflora, entire (or substantially entire) microbiota, or partially,substantially or completely isolated or purified fecal flora, islyophilized, freeze-dried or frozen, or processed into a powder.

For therapeutic use in the method of the present disclosure, acomposition may be conveniently administered in a form containing one ormore pharmaceutically acceptable carriers. Suitable carriers are wellknown in the art and vary with the desired form and mode ofadministration of the composition. For example, they may includediluents or excipients such as fillers, binders, wetting agents,disintegrators, surface-active agents, glidants, lubricants, and thelike. Typically, the carrier may be a solid (including powder), liquid,or combinations thereof. Each carrier is preferably “acceptable” in thesense of being compatible with the other ingredients in the compositionand not injurious to the subject. The carrier may be biologicallyacceptable and inert (e.g., it permits the composition to maintainviability of the biological material until delivered to the appropriatesite).

Oral compositions may include an inert diluent or an edible carrier. Forthe purpose of oral therapeutic administration, the active compound canbe incorporated with excipients and used in the form of tablets,troches, or capsules, e.g., gelatin capsules. Oral compositions can alsobe prepared by combining a composition of the present disclosure with afood. In one embodiment a food used for administration is chilled, forinstance, ice cream. Pharmaceutically compatible binding agents, and/oradjuvant materials can be included as part of the composition. Thetablets, pills, capsules, troches and the like can contain any of thefollowing ingredients, or compounds of a similar nature: a binder suchas microcrystalline cellulose, gum tragacanth or gelatin; an excipientsuch as starch or lactose, a disintegrating agent such as alginic acid,primogel, or corn starch; a lubricant such as magnesium stearate orsterotes; a glidant such as colloidal silicon dioxide; a sweeteningagent such as sucrose or saccharin; or a flavoring agent such aspeppermint, methyl salicylate, orange flavoring, or other suitableflavorings. These are for purposes of example only and are not intendedto be limiting.

The active compounds can also be prepared in the form of suppositories(e.g., with conventional suppository bases such as cocoa butter andother glycerides) or retention enemas for rectal delivery. The activecompounds may be prepared with carriers that will protect the compoundagainst rapid elimination from the body, such as a controlled releaseformulation, including implants. Biodegradable, biocompatible polymerscan be used, such as ethylene vinyl acetate, polyanhydrides,polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Suchformulations can be prepared using standard techniques. The materialscan also be obtained commercially from, for instance, Alza Corporationand Nova Pharmaceuticals, Inc. Liposomal suspensions can also be used aspharmaceutically acceptable carriers. These can be prepared according tomethods known to those skilled in the art.

A composition may be encapsulated. For instance, when the composition isto be administered orally, the dosage form is formulated so thecomposition is not exposed to conditions prevalent in thegastrointestinal tract before the colon, e.g., high acidity anddigestive enzymes present in the stomach and/or intestine. Theencapsulation of compositions for therapeutic use is routine in the art.Encapsulation may include hard-shelled capsules, which may be used fordry, powdered ingredients soft-shelled capsules. Capsules may be madefrom aqueous solutions of gelling agents such as animal protein (e.g.,gelatin), plant polysaccharides or derivatives like carrageenans andmodified forms of starch and cellulose. Other ingredients may be addedto a gelling agent solution such as plasticizers (e.g., glycerin and orsorbitol), coloring agents, preservatives, disintegrants, lubricants andsurface treatment.

Formulations suitable for rectal administration include gels, creams,lotions, aqueous or oily suspensions, dispersible powders or granules,emulsions, dissolvable solid materials, douches, and the like. Theformulations are preferably provided as unit-dose suppositoriescomprising the active ingredient in one or more solid carriers formingthe suppository base, for example, cocoa butter. Suitable carriers forsuch formulations include petroleum jelly, lanolin, polyethyleneglycols,alcohols, and combinations thereof. Alternatively, colonic washes withthe rapid recolonization deployment agent of the present disclosure maybe formulated for colonic or rectal administration.

Formulations suitable for oral administration may be provided asdiscrete units, such as tablets, capsules, cachets, syrups, elixirs,chewing gum, “lollipop” formulations, microemulsions, solutions,suspensions, lozenges, or gel-coated ampules, each containing apredetermined amount of the active compound; as powders or granules; assolutions or suspensions in aqueous or non-aqueous liquids; or asoil-in-water or water-in-oil emulsions.

Formulations suitable for transmucosal methods, such as by sublingual orbuccal administration include lozenges patches, tablets, and the likecomprising the active compound and, typically a flavored base, such assugar and acacia or tragacanth and pastilles comprising the activecompound in an inert base, such as gelatin and glycerine or sucroseacacia.

Formulations of the disclosure may be prepared by any suitable method,typically by uniformly and intimately admixing the pre-determined gutflora with liquids or finely divided solid carriers or both, in therequired proportions and then, if necessary, shaping the resultingmixture into the desired shape. In addition, the pre-determined gutflora will be treated to prolong shelf-life, preferably the shelf-lifeof the pre-determined gut flora will be extended via freeze drying.

Furthermore, a tablet may be prepared by compressing an intimate mixturecomprising a powder or granules of the active ingredient and one or moreoptional ingredients, such as a binder, lubricant, inert diluent, orsurface active dispersing agent, or by molding an intimate mixture ofpowdered active ingredient of the present disclosure. In addition to theingredients specifically mentioned above, the formulations of thepresent disclosure may include other agents known to those skilled inthe art, having regard for the type of formulation in issue. Forexample, formulations suitable for oral administration may includeflavoring agents and formulations suitable for intranasal administrationmay include perfumes.

The therapeutic compositions of the disclosure can be administered byany conventional method available for use in conjunction withpharmaceutical drugs, either as individual therapeutic agents or in acombination of therapeutic agents. The dosage administered will, ofcourse, vary depending upon known factors, such as the pharmacodynamiccharacteristics of the particular agent and its mode and route ofadministration; the age, health and weight of the recipient; the natureand extent of the symptoms; the kind of concurrent treatment; thefrequency of treatment; and the effect desired. A daily dosage of activeingredient can be expected to be about 0.001 to 1000 milligrams (mg) perkilogram (kg) of body weight.

Dosage forms (compositions suitable for administration) contain fromabout 1 mg to about 500 mg of active ingredient per unit. In thesepharmaceutical compositions, the active ingredient will ordinarily bepresent in an amount of about 0.5-95% weight based on the total weightof the composition.

Ointments, pastes, foams, occlusions, creams and gels also can containexcipients, such as starch, tragacanth, cellulose derivatives,silicones, bentonites, silica acid, and talc, or mixtures thereof.Powders and sprays also can contain excipients such as lactose, talc,silica acid, aluminum hydroxide, and calcium silicates, or mixtures ofthese substances.

Formulations suitable for rectal administration may be presented assuppositories by mixing with a variety of bases such as emulsifyingbases or water-soluble bases.

Formulations suitable for vaginal administration may be presented aspessaries, tampons, creams, gels, pastes, foams, or spray formulascontaining, in addition to the active ingredient, such carriers as areknown in the art to be appropriate. Suitable pharmaceutical carriers aredescribed in Remington's Pharmaceutical Sciences, Mack PublishingCompany, a standard reference text in this field.

The dose administered to a subject, especially an animal, particularly ahuman, in the context of the present disclosure should be sufficient toaffect a therapeutic response in the animal over a reasonable timeframe. One skilled in the art will recognize that dosage will dependupon a variety of factors including the condition of the animal, thebody weight of the animal, as well as the condition being treated. Asuitable dose is that which will result in a concentration of thetherapeutic composition in a subject that is known to affect the desiredresponse.

The size of the dose also will be determined by the route, timing andfrequency of administration as well as the existence, nature, and extentof any adverse side effects that might accompany the administration ofthe therapeutic composition and the desired physiological effect.

It will be appreciated that the compounds of the combination may beadministered: (1) simultaneously by combination of the compounds in aco-formulation or (2) by alternation, i.e. delivering the compoundsserially, sequentially, in parallel or simultaneously in separatepharmaceutical formulations. In alternation therapy, the delay inadministering the second, and optionally a third active ingredient,should not be such as to lose the benefit of a synergistic therapeuticeffect of the combination of the active ingredients. According tocertain embodiments by either method of administration (1) or (2),ideally the combination should be administered to achieve the mostefficacious results. In certain embodiments by either method ofadministration (1) or (2), ideally the combination should beadministered to achieve peak plasma concentrations of each of the activeingredients.

It will be appreciated by those skilled in the art that the amount ofactive ingredients in the combinations of the disclosure required foruse in treatment will vary according to a variety of factors, includingthe nature of the condition being treated and the age and condition ofthe patient, and will ultimately be at the discretion of the attendingphysician or health care practitioner. The factors to be consideredinclude the route of administration and nature of the formulation, theanimal's body weight, age and general condition and the nature andseverity of the disease to be treated.

The sample drug composition may be packaged into a shelf box and thenpackaged into an insulated corrugated box for shipment to the customerat the time of order. The sample drug composition is shipped afterthawing to 0° C. from the −80° C. long term storage freezer. To ensurethat the liquid suspension is adequately protected from fluctuations intemperature during shipment, the packaging system was subjected tovarying temperatures over a 24-hour period. The design for this testingprocess was adapted from the ASTM International F2825-10, StandardPractice for Climatic Stressing of Packaging Systems for Single ParcelDelivery. The goal of the testing was to ensure that the product did notexperience temperatures below an acceptable threshold (32° F. or 0° C.)or exceed an acceptable threshold (84° F. or 29° C.)

The product may be administered to patients having a variety ofdifferent medical conditions and may desirably impact these conditions.Some of the medical conditions that may be desirably impacted by includecardiovascular and/or peripheral vascular disease, allergies, obesity,hypoglycemia, constipation, celiac sprue (e.g., celiac disease),gastrointestinal cancer (e.g. gastrointestinal cancer is at least one ofstomach cancer, esophageal cancer, colon cancer gallbladder cancer,liver cancer, pancreatic cancer, colorectal cancer, anal cancer, andgastrointestinal stromal tumors), myoclonus dystonia, sacrolileitis,spondyloarthropatliy, spondylarthritis, proximal myotonic myopathy; anautoimmune disease nephritis syndrome, autism, travelers' diarrhea,small intestinal bacterial overgrowth, chronic pancreatitis, apancreatic insufficiency, chronic fatigue syndrome, benign myalgicencephalomyelitis, chronic fatigue immune dysfunction syndrome,Parkinson's Disease (PD), amyotrophic lateral sclerosis (ALS), multiplesclerosis (MS), degenerative neurological diseases, Grand mal seizuresor petitmal seizures, Steinert's disease, chronic infectiousmononucleosis, epidemic myalgic encephalomyelitis, idiopathicthrombocytopenic purpura (ITP), an acute or chronic allergic reactionobesity, anorexia, irritable bowel syndrome (IBS or spastic colon)Crohn's disease, irritable bowel disease (IBD), colitis, ulcerativecolitis or Crohn's colitis, chronic infectious mononucleosis, epidemicmyalgic encephalomyelitis, acute or chronic urticarial, lupus,rheumatoid arthritis (RA) or juvenile idiopathic arthritis (JIA),pre-diabetic syndrome, fibromyalgia (FM), Type I or Type II diabetes,acute or chronic insomnia, and attention deficit/hyperactivity disorder(ADHD).

In the case of humans, the present disclosure encompasses methods oftreatment of chronic disorders associated with the presence of abnormalenteric microflora. Such disorders include but are not limited to thoseconditions in the following categories: gastro-intestinal disordersincluding irritable bowel syndrome or spastic colon, functional boweldisease (FBD), including constipation predominant FBD, pain predominantFBD, upper abdominal FBD, nonulcer dyspepsia (NUD), gastro-oesophagealreflux, inflammatory bowel disease including Crohn's disease, ulcerativecolitis, indeterminate colitis, collagenous colitis, microscopiccolitis, chronic Clostridium difficile infection, pseudemembranouscolitis, mucous colitis, antibiotic associated colitis, idiopathic orsimple constipation, diverticular disease, AIDS enteropathy, small bowelbacterial overgrowth, coeliac disease, polyposis coil, colonic polyps,chronic idiopathic pseudo obstructive syndrome; chronic gut infectionswith specific pathogens including bacteria, viruses, fungi and protozoa;viral gastrointestinal disorders, including viral gastroenteritis,Norwalk viral gastroenteritis, rotavirus gastroenteritis, AIDS relatedgastroenteritis; liver disorders such as primary biliary cirrhosis,primary sclerosing cholangitis, fatty liver or cryptogenic cirrhosis;rheumatic disorders such as rheumatoid arthritis, non-rheumatoidarthritidies, non rheumatoid factor positive arthritis, ankylosingspondylitis, Lyme disease, and Reiter's syndrome; immune mediateddisorders such as glomeruionephritis, haemolytic uraemic syndrome,juvenile diabetes mellitus, mixed cryoglobulinaemia, polyarteritis,familial Mediterranean fever, amyloidosis, scleroderma, systemic lupuserythematosus, and Behcets syndrome; autoimmune disorders includingsystemic lupus, idiopathic thrombocytopenic purpura, Sjogren's syndrome,haemolytic uremic syndrome or scleroderma: neurological syndromes suchas chronic fatigue syndrome, migraine, multiple sclerosis, amyotrophiclateral sclerosis, myasthenia gravis, Gillain-Barre syndrome,Parkinson's disease, Alzheimer's disease, Chronic InflammatoryDemyelinating Polyneuropathy, and other degenerative disorders;sychiatric disorders including chronic depression, schizophrenia,psychotic disorders, manic depressive illness; regressive disordersincluding, Asbergers syndrome, Rett syndrome, attention deficithyperactivity disorder (ADHD), and attention deficit disorder (ADD); theregressive disorder, autism; sudden infant death syndrome (SIDS),anorexia nervosa; dermatological conditions such as chronic urticaria,acne, dermatitis herpetiformis and vasculitis disorders; andcardiovascular and/or vascular disorders and diseases.

EXAMPLES

The disclosure may be further clarified by reference to the followingExamples, which serve to exemplify some embodiments, and not to limitthe invention in any way.

Example 1 Confirmation of Sample Characterization Methods

Tests were completed to confirm the methods for characterizing a normalhuman stool sample. A Measurement Systems Analysis (MSA) was conductedto identify the components of variation in the test measurementdescribed above. To do this, 5 healthy human donors of different ages,genders, and body mass were recruited. Stool samples were collected fromeach donor, and processed according to predetermined standard methods.The resultant bacterial suspensions were plated and grown on the twodifferent plates described above (the CDC and the BBE plates).

The variables tested included: 5 different donors, 3 liquid to humanstool ratios, 2 plate types, 4 dilution levels per plate, 6 plates perdilution level, double counts (used to calculate error attributed tohuman plate counters), a total of 550 plates counted twice, and 20 runs(sets of plates).

The test measurements were analyzed with nested Gage R&R (repeatabilityand reproducibility) using Minitab 15 statistical software and the errorbands were evaluated. The test process was determined to be repeatableand reproducible within specified error bands. While it was recognizedthat not all microbes can be cultured and counted, this methoddemonstrates that a representative subset of microbes in the bacterialsuspension can be used as indicators of normal healthy human stoolsamples.

Example 2 Enema Bag and Port Durability

Three ethylene vinyl acetate (EVA) bags similar to sample bag 12 weretested to evaluate the durability of the ports when frozen at −80° C.Temperatures and time were used per manufacturing procedure to simulatefuture product production and handling. The bags were tested for leakagepre-freeze, pre-thaw and post-thaw. The bags were filled with 100 mL ofsaline solution and the ports were sealed. To determine if the sealsalong the edges of the bags were leaking, the bags were inverted todetermine if ports were completely sealed. The bags were placed in a 0°C. cooling bath for one hour, then placed in a −80° C. freezer for onemonth in varying orientations. Bag sample A was placed flat, bag sampleB was placed on a long side, and bag sample C was placed on a shortside. After one month, the bags were removed from the −80° C. freezerand inspected for ruptures, cracks, and leaks. Additionally, a drop testwas conducted by dropping the frozen EVA bags on corners, faces, andports from a height of 36 inches. Drop testing included dropping thesamples on corners, ports, and flat surfaces of the product to simulatepotential handling errors when removing future product from storage. Thebags were then re-inspected after each drop with the above criteria.Each drop test was repeated three times per sample except for theinitial inspection of the bag perimeter seal. All the sample bags passedall the tests (no leaking was detected).

The bags were then subjected to a thaw process. Each sample wassubmerged in a glycerol/water bath for 1 hour at 0° C. Samples were thenremoved, dried, and drop testing was repeated. Again, all the samplebags passed all the tests (no leaking was detected).

Example 3 Clinical Study

An MRT composition as disclosed herein was administered to 31 subjectsin a Phase 2 clinical study. No serious adverse events were reported,and no adverse events were associated with the product or itsadministration. Of the subjects, 27 subjects experienced successfulresolution of their rCDAD (recurrent clostridium difficile associateddiarrhea) symptoms after receiving either one or two doses of the MRTcomposition, defined by no recurrence of rCDAD symptoms for 56 daysfollowing administration. Of these 27 subjects, 16 experienced completeresolution of rCDAD after receiving one dose of the MRT composition,with the other 11 subjects recurring after the first administration, butthen successfully reaching the 56-day efficacy endpoint following asecond administration of the MRT composition. Of these subjects, 4subjects were considered treatment failures: 3 subjects experiencedrecurrence of rCDAD after receiving their second dose of the MRTcomposition, and 1 subject recurred after the first dose and did notreceive a second administration.

Doses of the MRT composition were randomly selected from the availablemanufactured clinical batches. The doses that were administered reflectproduct made from four donors. None of the product attributes (dosemass, viable microbes, shelf-life, thawed shelf-life, etc.) appear tocorrelate with the clinical outcome, or can be used to predict if a dosewill result in a successful outcome. The clinical result information isprovided at the end of this ID.

Information on the MRT Composition Doses Administered in the Phase 2Clinical Study:

45 doses of the MRT composition were thawed, shipped, and dosed to humanpatients. The age of the dose (AD) (which is the date of manufacture ofthe doses to date of administration to the clinical patient) arerepresented. The statistics associated with the several attributes ofthe MRT composition are provided below:

AD Average time=43.2 hours

AD Standard Deviation=14.9 hours

AD Minimum time=22.1 hours

AD Maximum time=73.8 hours

There appears to be no correlation or detriment to the clinical outcome(resolution of recurrent clostridium difficile associated diarrhea) andthese product attributes.

Example 4 Selection of a Cryoprotectant

The use of a cryoprotectant, in particular polyethylene glycol (PEG),has been found to maintain the viability (as determined by CFUs on CDCand BBE plates) of the MRT composition after freezing and re-thawing.This includes the time period from thawing, shipping in a controlledtemperature package and allowing for time from opening until treating apatient. As with the quality testing above, the final acceptable countranges for MRT products prior to being frozen can be between about 30 toabout 300 CFU at dilution level 10⁻⁶ on the CDC plates, and from about30 to about 300 CFU at dilution level 10⁻⁵ on the BBE plates. One methodof assuring that viability is maintained is the requirement of the enduser or customer, including, but not limited to, a physician orclinician, to use the product within 48 hours of receiving the product.Additionally, the end user will be required to store the product betweenabout 2 and about 29° C. until use.

The addition of a cryoprotectant was analyzed from two perspectives.First, several cryoprotectants were screened to evaluate the initialeffect of the addition of the cryoprotectant to the MRT product. Thistesting was used to determine mortality or viability of the MRT productwhen mixed with a particular cryoprotectant. The second perspectiveanalyzed was the actual freeze protection capability of a particularcryoprotectant on the MRT product when the MRT product was frozen andthen re-thawed for delivery to the patient. The result of this culturingindicated how viable the product remained after freeze/thaw.

Tests were completed to explore the effects of adding a variety ofdifferent potential MRT cryoprotectants to a homogenized and filteredhuman stool mixture (or MRT product). The tests were intended only toquantify the response of the bacteria to the initial addition of thecryoprotectant, and did not include testing whether the cryoprotectantwas successful in protecting the bacteria through a subsequentfreeze-thaw cycle. In these tests, single human stool donations weresplit among various tests, with a “control” sample of only normal,isotonic saline (i.e., no cryoprotectant added) used for a baseline.Both CDC plates and BBE plates were used. For all tests, a weightedaverage of CFU counts that combined the results of two differentdilution levels was used. The cryoprotectants used included: 10% skimmilk, 5% glycerol, 10% glycerol, 10% DMSO and polyethylene glycol (PEG)at molecular weights ranging from 600 to 20000.

For the CDC plates: 10% skim milk, 10% glycerol, and PEG all performedreasonably well, with CFU counts staying within approximately 25% of thesaline control. Of note, higher concentrations of glycerol resulted inconsiderable microbe mortality in a dose-dependent relationship.

For the BBE plates: Only the PEG formulations did not show significantmicrobe mortality. Of note, the 10% glycerol formulations yielded nearly90% mortality (10% survival), and the higher concentrations of glycerolyielded 100% mortality (as seen using the current dilution levels).

Given the results from the BBE plates of 10% glycerol, an additionalinvestigation was performed to see if the 90% mortality (on the BBEplate) from adding the glycerol could be eliminated. It was hypothesizedthat decreasing the glycerol concentration to 5%, or chilling themicrobial mixture prior to addition of the glycerol (to slow metabolicactivity) could reduce the anticipated high mortality. The 5% glycerolsolution had less mortality than the 10%, and cooling also decreased themortality in a dose-dependent relationship. However, these effects werenot strong enough to overcome the baseline results, and mortality of atleast 60% was seen on all tests in glycerol versus the control.

Maintaining the viability of microbes in a MRT product is critical fromtime of human stool collection to time of giving the MRT product dose toa patient. Therefore, it is important that the cryoprotectant added nothave a significant toxic effect on the microbes when initially added. Ofthe cryoprotectants tested, only the PEG formulations performed well.Skim milk did not perform particularly well with respect to the BBEresults. Additional drawbacks for the use of milk include the potentialfor increasing the chance of allergic reaction and the variablecharacterization profile of milk. Likewise, DMSO did not perform well onthe BBE plates. In addition, while DMSO is used topically in medicinalapplications, there are currently no known uses in the humangastrointestinal system. 10% glycerol performed well on the CDC plates,but exhibited 80-90% mortality (10-20% survival) on the BBE plates.

Example 5 Additional Cryoprotectants

Human gut microbiota were extracted from human stool into an aqueoussaline containing a number of different potential cryoprotectants at aspecific concentration. These solutions were tested for pH and culturedon CDC and BBE agar plates to measure the viable microbial load, thenwere frozen at −80 C for between 1 to 7 days, and then thawed. A samplefrom the thawed solution was then tested for pH and cultured on CDC andBBE agar plates to measure the viable microbial load. Cryoprotectantswith a screen result of “++” showed significantly greater viabilityresults compared to PEG3350 (and glycerol), those with “+” had resultsconsidered at least as good as glycerol, those with “0” had mixedresults and may or may not be suitable cryopreservatives, and those with“−” performed worse than glycerol and should not be considered effectivecryopreservatives for human gut microbiota solutions. The results, basedon pH measurements and enumeration of viable microbes using CDC and BBEagar plates suggested the following: dextrose, betaine, glycine,sucrose, polyvinyl alcohol, and Pluronic F-127 in DMSO had a resultscored as “++”. Mannitol, tween 80, ethylene glycol, 1,3-propanediol,hydroxypropyl cellulose, glycerol, PEG/glycerol mix, and propyleneglycol had a result scored as “+”. Propylene glycol (3% w/v) and fishoil had a result scored as “0”. Magnesium hydroxide, urea, and xanthangum had a score of “−+”. The scoring of “−+” is used to denote that thepH was found to be not acceptable but that plating results were found tobe acceptable.

Example 6 Example Production Process

Tests were completed to simulate an exemplary entire production processwherein a processed sample of human stool (diluted, homogenized, andfiltered) is cooled, frozen for long-term storage, thawed, shipped to acustomer site, and warmed to body temperature prior to retention enema.The production process simulated a nominal process for collection ofhuman stool; dilution of human stool directly into a cryoprotectionsolution (or diluent or saline/PEG mixture) at a 2:1 to a 4:1 ratio;nominal homogenization and filtration process; chilling of packagedproduct in a circulating fluid bath; long-term frozen storage; warmingof packaged product in a circulating fluid bath; packaging of productfor shipment with “cold packs” and in insulating materials; overnightshipping to customer; bedside warming of product for immediate infusioninto patient. As part of the study, three parameters were varied toexplore their effects on overall microbial viability or survival (asmeasured by serial dilution onto CDC and BBE plates for incubation andcounting of CFUs). These parameters included the use of acryoprotectant, temperature of a chilling bath, and temperature of athawing bath.

For cryoprotectant testing, the study included samples with nocryoprotectant (normal saline); 10% glycerol and PEG 3350 at 59 g/liter.For testing the use of a cooling bath, the study included samples thatwent directly into a freezer (−80° C.), and therefore, were notsubjected to a cooling bath, samples that went directly into a 0° C.cooling bath, and samples that went directly into a −11° C. coolingbath. The warming was tested at 0° C., +10° C., and +20° C. Each testpermutation was normalized to a control sample that used the samecryoprotectant, but plated immediately and NOT subjected to any of thefreeze-thaw processes.

The cryoprotectants, if used, were mixed with normal saline and addedduring the homogenization process (see definition of diluent andsaline/PEG mixture). Thus, any microbial mortality due to addition ofthe cryoprotectant (for example, such as has been seen with glycerol,especially in the BBE plates) will only be observed by comparing theCFUs of the control samples.

It was found that the freezing and thawing parameters had little effecton overall microbial survival. This is generally clear for the CDCplates, where the data is generally well behaved and the results, forall the freeze-thaw parameters, vary only well within a single log-levelof dilution. For the BBE plates, the raw data was much less wellbehaved, with several instances of apparent outliers and cases where the10× rule comparing adjacent dilution levels (i.e., log levels) wasviolated. However, there was still not an apparent difference due to thefreeze-thaw parameters.

Effects due to the different cryoprotectants used were clearly observed.For this analysis, a simple arithmetic mean of the results from thedifferent freeze-thaw parameters was used to compare cryoprotectantperformance. For the CDC plates, “no cryoprotection” had an 18% survival(82% mortality) through freeze-thaw, while the addition of glycerol andPEG reduced this mortality something on the order of 30% (67% and 75%survival, respectively). With respect to the samples treated withglycerol, the above results neglect the mortality from the initialaddition of the glycerol. When the initial addition of thecryoprotectant is added to the effects of the freeze/thaw, the magnitudeof this effect was around 80% mortality. This was compared to about 32%mortality for sample using PEG as cryoprotectant.

On BBE plates, the effect of adding glycerol was very high mortality at80% to 90%. In counterpoint, the PEG plates showed either low or noinitial toxicity from the cryoprotectant and a strong preservativeeffect through the freeze-thaw cycle. Overall cumulative survival usingPEG is 75% versus control (25% mortality). It was concluded that 10%glycerol performs poorly on BBE plates, based on the combination ofinitial mortality and freeze-thaw losses being on the order of 1-logloss (10% survival). The PEG-3350 performs well on both CDC and BBEplates. The PEG has low initial toxicity to the microbes (little or nolosses from addition of the cryoprotectant to the human stool) and itoffers significant protection versus “no cryoprotectant”. It isanticipated that each dose of MRT will have a minimum of 10⁷ microbes/mLof suspension, with a minimum of 100 mL of suspension delivered perdose.

Example 7 Fecal Transplant Kit

In an example, a kit of parts can be created to aid in fecal transplant.In an example, a donation kit can be shipped to a clinician. Thedonation kit can include equipment for blood and fecal samples from thepatient or, in certain examples, a healthy donor. Because much of thepatient's gut microbiota is anaerobic, many organisms can die withexposure to air. In an example, the donation kit can include materialsto ship the blood and fecal samples without harming the samples (e.g.,quick freeze, dry ice, etc.).

Once shipped to a facility (e.g., one location, regional locations, manylocations, etc.), the samples can be tested, and Clostridium difficileor the presence or absence of one or more other diseases or conditionscan be confirmed. In other examples, a healthy fecal sample can betested and prepared for use as a treatment.

In an example, once the patient's samples are tested to verify thedisease or condition, or the donor's samples are tested to verify healthor other compatibility (e.g., the existence of one or more desiredcondition, etc.), a treatment can be prepared (e.g., using the healthydonor fecal sample, at least a portion of one or more healthy storedfecal samples, such as material from a fecal bank, etc.) and shippedback to the clinician for delivery to and treatment of the patient. Incertain examples, the treatment is preserved (e.g., frozen, etc.) duringshipping. The kit can include the processed fecal sample or treatment ina sterile container, such as a nasogastric (NG) tube, a vial (e.g., foruse with a retention enema), a gastro-resistant capsule (e.g., acid-bioresistant to reach the intestinal tract, having a sterile outside), etc.In an example, once received, the clinician can store the contents in amanner to preserve the microbiota until ready to be inserted into thepatient.

Example 8 Extended Shelf Life Formulations

The long-term storage of the survivability of the healthy humanmicrobial content of donor stool was studied. Stool samples wereprocessed with and without a cryoprotectant and cooled/thawed at varyingcontrolled temperatures. Samples were then removed after 360 days (12months) of storage at −80° C. and −20° C., thawed at controlledtemperatures and plated on two types of agar plates (Center for DiseaseControl 5% Blood Agar (CDC) and Bacteroides Bile Esculin Agar (BBE)respectively). The overall Colony Forming Unit per milliliter (CFU/mL)was recorded and analyzed. From the study, samples preserved withoutcryoprotectant were analyzed first, followed by samples preserved withvarying concentrations of different cryoprotectants.

CDC plate counts grown from “No Cryoprotectant” samples demonstratedthat freezer temperature and storage time had significant impact on therecoverable CFU numbers. These data are consistent with data recorded atprevious time points. In this model, the R² values indicate thatapproximately 59% of the variation (Adj. R²) in the data is explained bythe model, a drop from approximately 80% demonstrated by the model after180 days (6 months) of storage.

When stored at −20° C., most of the samples produced CFU/mL counts whichfell below the lower limit considered acceptable for productspecification (10⁸ CFU/mL). In contrast, samples stored at −80° C.demonstrated counts that remained above the desired lower limit forproduct specification. From this, it was concluded that long-termstorage of samples prepared without the use of a cryoprotectant andstored at −80° C. was found to result in greater viability when comparedto samples stored at −20° C.

For the data collected from samples stored with cryoprotectant, thestorage time and freezer temp were the most significant factors for theCDC counts response in CFU/mL. Most of the variation seen in the data isexplained by storage time, freezer temp, and the interaction betweenthese, as can be seen by the R² values obtained at 0.59.

Samples combined with cryoprotectants and stored at −20° C. continued todemonstrate a more significant decrease in recoverable CFU/mL. Sampleruns begin to fall below the 10⁸ product specification limit between 60and 90 days (2 and 3 months) for samples stored at −20° C. The rate ofdecrease in amount of recoverable CFU/mL slows beyond 60 days (2 months)of storage. However, at −80° C. storage temperature, the recoverableCFU/mL counts remain relatively stable through 270 days (9 months) ofstorage. Additionally, most counts remained above the minimum productspecification limit of 10⁸ CFU/mL.

Storing samples at a lower freezer temperature and for less time has apositive effect on the counts—as time progresses further from the pointof manufacture, a reliable recovery of CFU/mL indicating the viablemicrobial population of the product becomes more difficult to guarantee.However, data suggests that the effect of storage time can be dampenedwith the addition of PEG 3550 as a cryoprotectant, as well as storingthe material at a low temperature (in this case, −80° C.).

Example 9 Extended Shelf Life Formulations

Human stool was processed as disclosed herein; an initial sample of theprocessed suspension was used to create serial dilutions for inoculationof agar plates. Once the sample was removed from the suspension, theremaining suspension (approx. 150 mL) was transferred to two (2)separate sterile EVA storage bags. Each bag was frozen at −80° C. forone week.

After one week, the bags were removed from the freezer and thawed perthe MRT composition batch protocol. The bags were sampled to measure theimmediate post-freeze recoverable CFU/mL count and diversity; eachsample was serially diluted and plated on CDC and BBE plates. The bagswere then stored at two different temperatures, 4° C. and 25° C., andsampled every 24 hours for 192 hours total.

Samples at each time point were also tested by a contract laboratory forbiodiversity by using 16s rRNA methodology. For each sample, RNA isextracted from the bacterial cells and replicated (“amplified”) using atag primer made from of a series of base pairs needed to initiate RNAreplication. After the RNA is amplified, the sequences are denoised—aprocess which determines the statistical probability of a correctly orincorrectly paired nucleotide set—and used to identify each organismusing BLASTn software from the National Center for BiotechnologyInformation (NCBI) sequence library. Identity of the organisms found ineach sample is determined by the length of the sequence containing themost consecutive statistically probably base pairs in a sample. Thefinal numbers (direct counts and percentages of identified organismsfrom phyla to species if applicable) are then reported to Rebiotix foruse in determining the change in biodiversity over time in each sample.

The product undergoes an initial drop in recoverable CFU/mL on both CDCand BBE plates once removed from the freezer and thawed (t=0 hour timepoint), consistent with observations from prior studies conducted byRebiotix (P-006, P-007, P-009, P-012).

The thawed product held at 25° C. maintained a higher overallrecoverable CFU/mL count than material stored at 4° C. over 192 hours.

Recoverable CFU/mL counted on all CDC plates, regardless of overallcount, were considered “stable” at both temperatures throughout theexperiment based on the Rebiotix measurement system (P-001). The CFU/mLresults at both storage temperatures stayed within one log from theinitial count at thaw to 192 hours.

Recoverable CFU/mL counted on BBE plates demonstrated an increase inrecoverable CFU/mL when stored at 25° C. compared to the originalpre-freeze sample over the course of 192 hours of storage. At 4° C.,however, the recoverable CFU/mL maintained an unchanging (less than onelog change) count throughout the 192 hour hold time.

Thawed product at both temperatures met Rebiotix product releasespecification throughout the 192 hour hold time, regardless of a gain orloss in CFU/mL count:

CDC post-freeze microbial load specification: 10⁷ to 10¹⁴ CFU/mL

BBE post-freeze microbial load specification: 10⁵ to 10¹⁴ CFU/mL

Results currently collected from this study indicate that recoverablephenotypic diversity on the CDC plates most closely matches the originalsample diversity prior to freezing when product is stored at 25° C.post-thaw. In addition, both samples met the Rebiotix product releasespecification for diversity over time of ≧3 unique colony phenotypes.

Genetic biodiversity characterization (16s rRNA) of the samples isconducted by a contract laboratory examining the total bacterial types(to species if possible) as well as the percent concentrations of thesetypes of bacteria present in the samples over time.

Preliminary understanding of product behavior during a holding period ofup to 192 hours at two different temperatures continues to meet Rebiotixproduct release standards of CFU/mL per when used to inoculate CDC andBBE plates. More work is needed to confirm these findings. 16 s rRNAdata of each time point is currently under analysis.

Example 10 16s rRNA Data

The present disclosure provides compositions that include fecalmicrobes. As used herein, the term “fecal microbes” refers tomicroorganisms that are present in the gut, intestine, or colon,preferably colon, of a normal healthy adult human. Such a compositionmay be prepared by processing fecal material as disclosed herein. Asused herein, the term “fecal material” refers to human stool.Unprocessed fecal material contains non-living material and biologicalmaterial. The “non-living material” may include, but is not limited to,dead bacteria, shed host cells, proteins, carbohydrates, fats, minerals,mucus, bile, undigested fiber and other foods, and other compoundsresulting from food and metabolic waste products and partial or completedigestion of food materials. “Biological material” refers to the livingmaterial in fecal material, and includes microbes including prokaryoticcells such as bacteria and archea (e.g., living prokaryotic cells andspores that can sporulate to become living prokaryotic cells),eukaryotic cells such as protozoa and fungi, and viruses. “Biologicalmaterial” may also refer to the living material (e.g., the microbes,eukaryotic cells, and viruses) that are present in the colon of a normalhealthy human. Examples of prokaryotic cells that may be present in acomposition of the present disclosure include cells that are members ofthe class Actinobacteria, such as the subclass Actinobacteridae orCoriobacteridae, such as the order Bifidobacteriales orCoriobacteriales, and/or such as the family Bifidobacteriaceae orCoriobacteriaceae; members of the phylum Bacteroidetes, such as classBacteroidia, such as class Bacteroidales, and/or such as familyBacteroidaceae or Rikenellaceae; members of the phylum Firmicutes, suchas class Bacilli, Clostridia, or Erysipelotrichi, such as orderBacillales or Lactobacillales or Clostridales or Erysipelotrichales,and/or such as family Paenibacillaceae or Aeroccaceae orLactobacillaceae or Streptococcaceae or Catabacteriaceae orPeptococcaceae or Peptostreptococcaceae or Ruminococcaceae orClostridiaceae or Eubacteriaceae or Lachnospiraceae orErysipelotrichaceae; members of the phylum Proteobacteria, such as classAlphaproteobacteria or Betaproteobacteria or Gammaproteobacteria, suchas order Rhizobiales or Burkholderiales or AJteromonadales orEnterobacteriales, and/or such as family Rhodobiaceae orBurkholderiaceae or Shewanellaceae or Enterobacteriaceae; members of thephylum Tenericutes, such as the class Mollicutes, such as the orderEntomoplasmatales, and/or such as the family Spiroplasmataceae; and/ormembers of the class Verrucomicrobiae, such as the orderVerrucomicrobiales, and/or such as the family Verrucomicrobiaceae. Theseare just examples.

The MRT compositions of the present disclosure may include bacteria thatare members of at least 1 phylum, at least 2 phyla, at least 3 phyla, atleast 4 phyla, at least 5 phyla, at least 6 phyla, at least 7 phyla, atleast 8 phyla, at least 9 phyla, or at least 10 phyla. In at least someembodiments, the MRT compositions of the present disclosure may includebacteria that are members of at least 1 class, at least 2 classes, atleast 3 classes, at least 4 classes, at least 5 classes, at least 6classes, or at least 7 classes. In at least some embodiments, the MRTcompositions of the present disclosure may include bacteria that aremembers of at least 1 order, at least 2 orders, at least 3 orders, atleast 4 orders, at least 5 orders, at least 6 orders, or at least 7orders. In at least some embodiments, the MRT compositions of thepresent disclosure may include bacteria that are members of at least 1family, at least 2 families, at least 3 families, at least 4 families,at least 5 families, at least 6 families, at least 7 families. In atleast some embodiments, the MRT compositions of the present disclosuremay include bacteria that are members of at least 5, at least 10, atleast 20, or at least 30 different genera of bacteria. In at least someembodiments, the MRT compositions of the present disclosure may includeat least 10, at least 50, at least 100, at least 200, at least 300, orat least 400 different species of bacteria.

Samples of manufactured MRT compositions (manufactured as disclosedherein) were provided to Research and Testing Laboratory, Lubbock, Tex.for 16sRNA amplification and sequencing using the Illumina MiSeqplatform. The purpose of this analysis was to obtain data useful for:validating the tentative potency release assays; and evaluating theintra- and inter-donor bacterial diversity and consistency.

The 16s rRNA analysis of all product batches demonstrated that theprocess disclosed herein resulted in desirable bacterial diversityprofiles consistent. The data also indicated that the manufacturingprocess preserved a level of bacterial diversity consistent with normalfeces and considered viable for the treatment of recurrent C. difficile,including the maintenance of the predominant phyla, Bacteroidetes andFirmicutes.

In addition, product made from the stool of individual donors over timemaintained a very similar diversity profile. Table 2 presents acondensed version of the data, highlighting the means and standarddeviations for percent bacteria by Order for all batches manufacturedand tested. These “Order” categories represent the most commonlyidentified bacterial communities in the product batches.

TABLE 2 All batches (60) compared by Order Kingdom Phylum Class OrderAverage % Std Dev Bacteria Bacteroidetes Bacteroidia Bacteroidales 59 15Bacteria Firmicutes Bacilli Lactobacillales 0 1 Bacteria FirmicutesClostridia Clostridiales 35 11 Bacteria Firmicutes Unknown Unknown 1 1Bacteria Proteobacteria Betaproteobacteria Burkholderiales 0 0 BacteriaProteobacteria Gammaproteobacteria Enterobacteriales 0 0 No Hit No HitNo Hit No Hit 5 6

Example 11 16s rRNA Data—Individual Donors

To further illustrate the consistency of product manufacturing, multiplebatches of product made from the same donor over time were analyzed. Thefollowing tables indicate that, over the clinical trial manufacturingperiod, multiple batches of product from a single donor exhibitedsimilar diversity profiles. The microbiota for each donor was analyzedby bacterial Family to ensure that the trends in diversity wouldcontinue at a finer genetic level. The Shannon Diversity Index (alsoindicated by H′) is an industry-accepted method of reporting theabundance and evenness of organisms present in the microbiome, and wasused throughout this example. It has been shown to most completelyencompass the variation in sampling depth and is therefore relevant fordescribing a complex microbial community.

The bacterial diversity of Donor 1 is summarized in Table 3.

TABLE 3 Donor 1-Means and Variation of Batches by Bacterial FamilyFamily Average % Standard Deviation Bacteroidaceae 36 7 Bacteroidales(Unknown) 0 0 Clostridiaceae 6 2 Clostridiales (family) 0 0Clostridiales (Unknown) 7 3 Enterobacteriaceae 0 0 Eubacteriaceae 6 1Lachnospiraceae 4 1 Porphyromonadaceae 2 1 Prevotellaceae 1 0Rikenellaceae 5 2 Ruminococcaceae 18 3 Staphylococcaceae 0 6Streptococcaceae 0 0 XNo Hit 15 6

The Shannon Diversity index for multiple samples from Donor 1 issummarized in Table 4.

TABLE 4 Donor 1-Shannon Diversity Index Shannon Diversity Batch ID Index(H′) 13000-071713 1.91 13000-072913 1.96 13000-080513 1.96 13000-0806131.81 13000-092313 1.87 13000-092613 2.00 13000-110613 1.80 13000-0213141.78 AVERAGE 1.89 ST DEV 0.08

The bacterial diversity of Donor 2 is summarized in Table 5.

TABLE 5 Donor 2- Means and Variation of Batches by Bacterial FamilyFamily Average % Standard Deviation Bacteroidaceae 43 13 Clostridiaceae2 2 Clostridiales (family) 4 3 Eubacteriaceae 6 3 Firmicutes (Unknown) 00 Lachnospiraceae 1 0 Porphyromonadaceae 3 1 Rikenellaceae 23 20Ruminococcaceae 14 7 Streptococcaceae 1 1 XNo Hit 2 1

The Shannon Diversity index for multiple samples from Donor 2 issummarized in Table 6.

TABLE 6 Donor 2-Shannon Diversity Index Shannon Diversity Index Batch ID(H′) 13001-080613 1.45 13001-080913 1.70 13001-081213 1.46 13001-1125131.44 13001-121013 1.64 AVERAGE 1.54 ST DEV 0.12

The bacterial diversity of Donor 3 is summarized in Table 7.

TABLE 7 Donor 3 - Means and Variation of Batches by Bacterial FamilyFamily Average % Standard Deviation Bacteroidaceae 70 11 Burkholderiales(Unknown) 0 0 Clostridiaceae 7 3 Clostridiales (Unknown) 5 2Eubacteriaceae 4 2 Firmicutes (Unknown) 0 0 Lachnospiraceae 1 1Porphyromonadaceae 1 1 Rikenellaceae 0 0 Ruminococcaceae 10 5Streptococcaceae 0 0 No Hit 1 0

The Shannon Diversity index for multiple samples from Donor 3 issummarized in Table 8.

TABLE 8 Donor 3 - Shannon Diversity Index Batch ID Shannon DiversityIndex (H′) 13003-071613 1.19 13003-081313 0.98 13003-082013 1.0413003-082713 1.06 13003-082913 1.01 13003-090513 1.17 13003-090913 1.1013003-091113 0.78 13003-091213 0.76 13003-091313 1.02 13003-092513 1.2113003-100213 0.97 13003-101013 1.23 13003-101513 0.42 13003-110513 1.7013003-111913 1.22 13003-120213 1.28 13003-021414 1.28 13003-021714 1.1813003-021914 1.45 AVERAGE 1.08 ST DEV 0.27

The bacterial diversity of Donor 4 is summarized in Table 10.

TABLE 10 Donor 4-Means and Variation of Batches by Bacterial FamilyFamily Average % Standard Deviation Bacteroidaceae 44 12 Burkholderiales(Unknown) 1 1 Clostridiaceae 4 1 Clostridiales (Unknown) 6 2Eubacteriaceae 8 5 Firmicutes (Unknown) 1 1 Lachnospiraceae 9 4Porphyromonadaceae 1 0 Rikenellaceae 5 2 Ruminococcaceae 17 8Streptococcaceae 0 1 XNo Hit 2 3

The Shannon Diversity index for multiple samples from Donor 4 issummarized in Table 11.

TABLE 11 Donor 4-Shannon Diversity Index Batch ID Shannon DiversityIndex (H′) 13004-071513 1.65 13004-071613 1.93 13004-071813 1.7513004-072213 1.89 13004-072313 1.97 13004-072913 1.46 13004-073113 1.3413004-080513 1.64 13004-080713 1.79 13004-080813 1.72 13004-090313 1.6413004-090413 1.98 13004-100913 1.46 13004-102913 1.87 13004-103113 1.8013004-110413 1.56 13004-111913 1.77 13004-112113 1.78 13004-120213 1.8413004-021414 2.02 13004-021814 1.56 AVERAGE 1.73 ST DEV 0.18

The bacterial diversity of Donor 5 is summarized in Table 12.

TABLE 12 Donor 5-Means and Variation of Batches by Bacterial FamilyFamily Average % Standard Deviation Bacteroidaceae 48 6 Bacteroidales(Unknown) 0 0 Burkholderiales (Unknown) 0 0 Clostridiaceae 5 2Clostridiales (Unknown) 4 1 Eubacteriaceae 5 2 Lachnospiraceae 4 0Porphyromonadaceae 1 1 Rikenellaceae 4 1 Ruminococcaceae 18 5Sutterellaceae 0 0 No Hit 9 5

The Shannon Diversity index for multiple samples from Donor 5 issummarized in Table 13.

TABLE 13 Donor 5-Shannon Diversity Index Shannon Diversity Index BatchID (H′) 13005-080713 1.75 13005-081513 1.65 13005-100113 1.8313003-110513 1.71 13005-110613 1.52 13005-120913 1.65 AVERAGE 1.68 STDEV 0.11

The bacterial diversity of Donor 6 is summarized in Table 14.

TABLE 14 Donor 6 - Means and Variation of Batches by Bacterial FamilyFamily Average % Standard Deviation Bacteroidaceae 48 NA Bacteroidales(Unknown) 0 NA Burkholderiales (Unknown) 0 NA Clostridiaceae 5 NAClostridiales (Unknown) 4 NA Eubacteriaceae 5 NA Lachnospiraceae 4 NAPorphyromonadaceae 1 NA Rikenellaceae 4 NA Ruminococcaceae 18 NASutterellaceae 0 NA No Hit 9 NA

The Shannon Diversity index for multiple samples from Donor 6 issummarized in Table 15.

TABLE 15 Donor 6-Shannon Diversity Index Shannon Diversity Index BatchID (H′) 13008-021314 1.59 AVERAGE NA ST DEV NA

Due to the fact that only one batch was manufactured from Donor 6, noAverage (H′) or Standard Deviation of the (H′) could be calculated atthis time.

16s rRNA molecular characterization of the MRT composition as disclosedherein indicates that considerable bacterial diversity is preservedthrough the manufacturing process. While there are fluctuations inrelative amounts of various bacteria between donors, the variation asmeasured by the standard deviation of the average percentages ofspecific bacterial Orders is quite small. Diversity profiles of productmade from individual donors collected over time, demonstrated a highdegree of similarity at the Family level (see Tables for Donors 1-5). Incontrast, 16s data for microbes commonly associated with disease inpatients were noticeably absent in the MRT compositions made fromhealthy donors. Product batches evaluated in this analysis were used inthe Phase 2 clinical study, which demonstrated an 87% cure rate withacceptable mild to moderate adverse events. This data is important as italso substantiates that the level of bacterial diversity in MRTcomposition as disclosed herein provided therapeutic benefit.

Experiment 12 Success/Failure by Donor Gender

The success of treatments using the MRT compositions disclosed hereinwere tabulated taking into account the gender of the donor. It wasobserved that treatment success after a single dose of the MRTcomposition was greater when the fecal donor (whose fecal sample wasutilized in manufacturing the MRT composition) was male. Since the Dose2 response is more similar among the donors and these doses weredelivered to antibiotic naïve patients (no antibiotic pretreatment andwith active disease), it may be that the flora from the female donorsare more susceptible to antibiotics.

TABLE 16 Success/Failure by Donor Gender Patient Patient Dose 1 Dose 2Donor Success Failure Success Failure F 2/11 (18%) 9/11 (82%) 3/4 (75%) 1/4 (25%) M 7/10 (70%) 3/10 (30%) 3/5 (60%)  2/5 (40%) F  4/9 (44%)  5/9(56%) 4/4 (100%) M  3/3 (100%) 1/1 (100%)

Experiment 13 Donor Vs. Patient Effects

Fecal obiota transplantation (FMT) is becoming an increasingly acceptedtreatment for recurrent Clostridium difficile infection (CDI). Overallresolution rates in the range of 90% have been reported in theliterature, although multiple doses may be necessary to achieve thiscure rate. Conventional procedure has been to use a second donor in caseof treatment failure. This experiment examines whether it is necessaryto use a second donor.

Methods

A total of 34 patients with recurrent CDI enrolled at 11 sites in theU.S. received 1 or 2 doses of RBX2660 (microbiota suspension) via enemabetween August 2013 and January 2014 as part of this study. Perprotocol, a second dose was permitted if symptoms reoccurred <8 weeksafter the first dose. Patients who required 2 doses could receiveRBX2660 manufactured from the same or different donors. The same pair ofdonors could also be used in a different order. Efficacy was defined asthe absence of CDI at 8 weeks after the last treatment. A nestedmathematical model was used to determine whether the specific donoreffected the results.

Sourcing

The RBX2660 (microbiota suspension) tested was designed to mimic FMT andused human stool as raw material. The RBX2660 was formulated to have along shelf-life and was supplied in ready-to-use enema format, in 50g/150 mL doses. The RBX2660 was manufactured using standardized,quality-controlled processes and contained a minimum guaranteed quantityof live microbes. Four donors were used to prepare the RBX2660 used inthe study. Donations were not pooled and were made on site at RebiotixInc., Roseville, Minn. The same batch was used in 1-4 patients. Donorswere randomized to patients for both the first and second doses. Theproduct was manufactured in donor-specific batches that could be trackedto individual patients and outcomes.

Nested Mathematical Model

A mixed model was used to predict treatment success taking into accountdonors and dose number. Repeated measures data was included to accountfor patients who received 2 doses of RBX2660. In this analysis, apatient was classified as either a success or failure for both doses.Donor 1 was used as the reference donor for comparative purposes as noevidence was seen that the other donors had a different success rate.P<0.05 indicates statistical significance; all analyses were done usingthe R statistical package.

Results

A total of 34 patients (mean age 68.8 years, 67.6% female) received atleast 1 dose of RBX2660. Nineteen patients received 1 dose and 15patients received 2 doses. Success was not impacted by the donor or doseorder.

TABLE 17 LOGISTIC REGRESSION MODELING FOR ALL PATIENTS AND ALL DOSESEstimate Std. Error z Value P r(>ABS(z)) Intercept 1.174 0.730 1.6090.108 As factor - −0.564 1.226 −0.460 0.645 Donor 3 As factor - 1.7231.271 0.569 0.569 Donor 4 As factor - 15.292 2399.545 0.006 0.995 Donor5* As factor - 0.101 1.061 0.095 0.924 Donor 2 *Donor 5 contributed acomparatively small number of doses and was not significant comparedwith donor 1. There was a large standard deviation resulting from thesmall sample size. All P values in the logistical model were >.05,indicating no donor effect.

TABLE 18 LOGISTIC REGRESSION MODELING FOR PATIENTS RECEIVING TWO DOSESEstimate Std. Error z Value P r(>ABS(z)) Intercept 1.554 0.711 2.1860.029 As factor - −0.115 0.934 −0.123 0.902 Donor 3 As factor - 1.0601.236 0.858 0.391 Donor 4 As factor - 16.221 2267.846 0.007 0.994 Donor5* As factor - −0.559 0.872 −0.641 0.522 Donor 2 *Donor 5 contributed acomparatively small number of doses and was not significant comparedwith donor 1. There was a large standard deviation resulting from thesmall sample size. All P values in the logistical model were >.05,indicating no donor effect.

Conclusions

Based on an analysis of small numbers, it appears that the specificdonor does not affect the outcomes achieved with administration ofRBX2260 for recurrent CDI. The results suggest that outcomes arepatient-specific and it is not necessary to switch donors in order toachieve a cure if the first dose fails. Additional research with alarger patient cohort along with in-depth comparative analysis of donorand patient microbiota is suggested to provide more details onpatient-specific factors impacting success or failure with this therapy.

Case Study

An 89 year old white female with history of recurrent diarrhea receiveda first dose of RBX2660 on Sep. 16, 2013. The first dose waswell-tolerated and stool normalized. On Sep. 30, 2013, CDI symptomsreturned. Patient received a second dose, without antibioticpre-treatment, on Oct. 3, 2013. Second dose was well-tolerated. No CDIsymptoms through six month follow-up.

16s rRNA Analysis

Patient's stool was characterized using 16S rRNA analysis at 7 daysafter the first dose of RBX2660 and at 7, 30, and 60 days after thesecond dose and compared with donor's fecal microbiota. The extractionwas completed by Research and Testing Laboratory, Lubbock, Tex.;analysis was conducted by the Bushman Laboratory, University ofPennsylvania, Philadelphia, Pa. A heat map of the patient's samplesindicated the patient's fecal microbiota begins, over time, to resemblethat of the donor. However, there is not a close correlation.

U.S. Patent Application No. 61/337,283 is herein incorporated byreference.

U.S. Patent Application No. 61/351,184 is herein incorporated byreference.

U.S. patent application Ser. No. 13/576,573, published as U.S. PatentApplication Pub. No. US 2013/0045274, is herein incorporated byreference.

U.S. patent application Ser. No. 14/093,913, published as U.S. PatentApplication Pub. No. US 2014/0086877, is herein incorporated byreference.

It should be understood that this disclosure is, in many respects, onlyillustrative. Changes may be made in details, particularly in matters ofshape, size, and arrangement of steps without exceeding the scope of thedisclosure. This may include, to the extent that it is appropriate, theuse of any of the features of one example embodiment being used in otherembodiments. The invention's scope is, of course, defined in thelanguage in which the appended claims are expressed.

What is claimed is:
 1. A method of treating a gastrointestinal disorder,the method comprising: administering a first microbiota restorationtherapy composition to a patient, the first microbiota restorationtherapy composition derived from a unique donor; ascertaining a need forfurther treatment; and administering a second microbiota restorationtherapy composition to the patient, the second microbiota restorationtherapy composition derived from the unique donor.
 2. The method ofclaim 1, wherein the first microbiota therapy composition comprises amixture of fecal microbiota and polyethylene glycol.
 3. The method ofclaim 1, wherein administering a first microbiota restoration therapycomposition to a patient comprises administering one or more doses ofthe first microbiota restoration therapy composition.
 4. The method ofclaim 1, wherein administering a second microbiota restoration therapycomposition to a patient comprises administering one or more doses ofthe second microbiota restoration therapy composition.
 5. The method ofclaim 1, further comprising administering a pre-treatment antibiotic. 6.The method of claim 1, further comprising administering a post-treatmentantibiotic.
 7. The method of claim 1, wherein administering a firstmicrobiota restoration therapy composition to a patient comprisesadministering an enema.
 8. The method of claim 1, wherein administeringa second microbiota restoration therapy composition to a patientcomprises administering an enema.
 9. The method of claim 1, whereinascertaining a need for further treatment comprises recognizing that thepatient is still suffering from the gastrointestinal disorder.
 10. Themethod of claim 1, wherein the gastrointestinal disorder comprises a C.difficile infection.
 11. A method of treating a gastrointestinaldisorder, the method comprising: administering a pre-treatmentantibiotic to a patient with a gastrointestinal disorder; administeringa primary dosage of a microbiota restoration therapy composition to apatient; ascertaining a need for further treatment; and administering asecondary dosage of the same microbiota restoration therapy compositionto the patient.
 12. The method of claim 11, wherein the microbiotarestoration therapy composition is derived from a single donor.
 13. Themethod of claim 11, wherein the pre-treatment antibiotic comprisesvancomycin, fidaxomicin, rifaximimin, linezolid, daptomycin,quinupristin-dalfopristin, tigecycline, ceftaroline, ceftobiprole,televancin, teicoplanin, dalbavancin, metronidazole, ortivancin, or acombination thereof.
 14. The method of claim 11, further comprisingadministering a post-treatment antibiotic.
 15. The method of claim 11,further comprising manufacturing the microbiota restoration therapycomposition and wherein manufacturing the microbiota restoration therapycomposition comprises: collecting a human fecal sample; addingpolyethylene glycol to the human fecal sample to form a diluted sample;mixing the diluted sample with a mixing apparatus; filtering the dilutedsample; wherein filtering forms a filtrate; transferring the filtrate toa sample bag; and sealing the sample bag.
 16. The method of claim 11,wherein administering the first dosage of the microbiota restorationtherapy composition to a patient comprises administering one or moredistinct doses of the microbiota restoration therapy composition. 17.The method of claim 11, wherein administering the second dosage of themicrobiota restoration therapy composition to a patient comprisesadministering one or more distinct doses of the microbiota restorationtherapy composition.
 18. A method of treating a gastrointestinaldisorder, the method comprising: administering a pre-treatmentantibiotic to a patient with a gastrointestinal disorder; administeringa primary dosage of a microbiota restoration therapy composition derivedfrom a unique donor to a patient, the microbiota restoration therapycomposition pre-screened for bacterial diversity; ascertaining a needfor further treatment; and administering a secondary dosage of themicrobiota restoration therapy composition derived from the unique donorto the patient.
 19. The method of claim 18, wherein the microbiotarestoration therapy composition includes bacterial from at least sevendifferent families and has a Shannon Diversity Index of 0.4-2.5 whencalculated at the family level.
 20. The method of claim 18, wherein theprimary dosage of a microbiota restoration therapy composition isadministered with an enema tube.